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The striated muscle sarcomere is a force generating and transducing unit as well as an 
important sensor of extracellular cues and a coordinator of cellular signals resulting in 
various adaptive responses. As an example, mechanical signals (e.g. stretch) are sensed at 
the sarcomeric Z-disk and converted to biochemical events and changes in transcriptional 
activity. Myotilin, a Z-disk component identified by us, interacts with Z-disk core 
structural proteins and with regulators of signaling cascades and MuRF ubiquitin ligases. 
Missense mutations in the gene encoding myotilin cause two types of dominantly 
inherited disorders, myofibrillar myopathy (MFM) and limb-girdle muscular dystrophy 
1A (LGMD1A) as well as cardiomyopathy by an unknown mechanism. 
In this thesis, consisting of three publications, the functions of myotilin were further 
characterized to clarify the molecular biological basis and the pathogenetic mechanisms of 
inherited muscle disorders, mainly LGMD1A, MFM, and cardiomyopathy caused by 
mutated myotilin. 
Myotilin has an important function in the assembly and maintenance of the Z-disks 
probably through its actin-organizing properties. We used a number of truncated and 
mutated myotilin variants and several cell biological and biochemical methods, including 
transposon mutagenesis and yeast two-hybrid method, to further dissect its unique actin 
binding and bundling functions. Our results show that the Ig-domains of myotilin are 
needed for both binding and bundling actin and define the Ig domains as actin-binding 
modules. The disease-causing mutations appear not to change the interplay between actin 
and myotilin. 
Interactions between Z-disk proteins regulate muscle functions and disruption of these 
interactions results in muscle disorders. Mutations in Z-disk components myotilin, 
ZASP/Cypher and FATZ-2 (calsarcin-1/myozenin-2) are associated with myopathies. We 
used various biochemical binding assays, including AlphaScreen and PDZ array 
membranes, bioinformatics, microscopy and phosphorylation experiments to study the 
potential interplay between myotilin, ZASP and FATZ-2. We showed that proteins from 
the myotilin and FATZ (calsarcin/myozenin) families interact via a novel and unique type 
of class III PDZ binding motif with the PDZ domains of ZASP/Cypher and other Enigma 
family members and that the interactions can be modulated by phosphorylation. 
The morphological findings typical of myotilinopathies include Z-disk alterations and 
aggregation of dense filamentous material. The causes and mechanisms of protein 
aggregation in myotilinopathy patients are unknown, but it has been suggested that 
impaired degradation might explain in part the abnormal protein accumulation. We 
explored, whether myotilin is degraded by the calcium-dependent, non-lysosomal cysteine 
protease calpain and by the proteasome pathway, and whether wild type and mutant 
myotilin differ in their sensitivity to degradation. We showed that myotilin is a substrate 
for calpain and mapped two of the calpain cleavage sites by mass spectrometry. These 
studies identify the first functional difference between mutated and wild type myotilin. 
Furthermore, if degradation of myotilin is disturbed, it accumulates in cells in a manner 






where mutant myotilin escapes proteolytic breakdown and forms protein aggregates, 
leading to disruption of myofibrils and muscular dystrophy. 
In conclusion, the main results of this study demonstrate that myotilin is a Z-disk 
structural protein interacting with several Z-disk components. The turnover of myotilin is 
regulated by calpain and the ubiquitin proteasome system and mutations in myotilin seem 
to affect the degradation of myotilin, leading to protein accumulations in cells. These 
findings are important for understanding myotilin-linked muscle diseases and designing 






Review of the literature 
1. The cytoskeleton 
Eukaryotic cells have internal scaffolding called the cytoskeleton that gives them their 
distinctive shapes. It also enables the cell to move or the muscle cell to contract and is 
required for cell division and transport of organelles inside the cell. 
The cytoskeleton is an organized network of three different, but interconnected 
filament structures: microtubules, the intermediate filaments, and microfilaments. The 
cytoskeleton is not a static structure, as its name implies, but cytoskeletal polymers are 
highly dynamic, capable of polymerizing, depolymerizing, and moving within the 
cytoplasm on a time scale of seconds to minutes. All three types of filaments form as 
helical assemblies of subunits that self-associate using a combination of end-to-end and 
side-to-side protein contacts. The three cytoskeletal systems are interconnected via 
proteins that are able to bind the different cytoskeletal proteins. For instance, during cell 
division and cell migration, microtubule and actin cytoskeletons need to perform their 
tasks in an orderly manner (reviewed in Frixione, 2000). 
Microtubules are strong, rigid hollow tubes. They function in organizing the cytoplasm 
and transporting organelles like vesicles or mitochondria within the cytoplasm. In 
intracellular trafficking, the vesicles glide along the microtubules with the help of motor 
proteins (such as kinesin and dynein) to their targets. During cell division, a large dynamic 
array of microtubules, the mitotic spindle, functions to physically segregate the 
chromosomes and to orient the plane of cell cleavage. Microtubules are also involved in 
neurite outgrowth and the movement of flagella and cilia (reviewed in Gardner et al., 
2008). 
Intermediate filaments are rope-like protein fibers that tolerate stretching and bending 
and are hard to break. The nuclear lamins form a network of filaments on the inner surface 
of the nuclei and create a structural scaffold for the nuclear envelop. The cytoplasmic 
intermediate filaments are not required in every cell type and these intermediate filaments 
are very diverse. Keratin filaments in epithelial cells form skin, nails and hair and 
neurofilaments provide mechanical strength in nerve cells and desmin filamnets in muscle 
cells (reviewed in Chang & Goldman, 2004). 
Many debilitating human diseases, including cancer, developmental diseases, and 
neurodegenerative diseases, are linked to defects in the cytoskeleton (Lundin et al., 2010). 
1.2 The actin cytoskeleton 
Actin is the most abundant intracellular protein in a eukaryotic cell. In muscle cells, for 
example, actin comprises 10 % by weight of the total cell protein and in nonmuscle cells, 
up to 5 % of the cellular protein is actin. The 42 kDa actin monomer is encoded by a large, 
highly conserved gene family. The amount of actin genes varies from one in some single-






instance, humans have six actin isoforms coded by separate genes, which are divided into 
three groups: alpha (α), beta (β), and gamma (γ) and some plants have as many as 60 actin 
isoforms (Khaitlina, 2001). 
The most variable region in the actin molecule is the N-terminal end. Although the 
isoforms differ at only four or five positions, they have different functions. In vertebrates, 
α-actins are expressed mainly in muscle cells (α-skeletal, α-cardiac, α-smooth muscle, and 
γ- smooth muscle). In human skeletal muscles, α-skeletal actin is the predominant isoform 
while α -cardiac actin is the most abundant isoform in the heart tissue. Furthermore, α -
smooth muscle actin is the major isoform in vascular tissues such as the aorta, while γ-
smooth muscle actin predominates in the gastrointestinal and genital tracks. β- and γ- 
isoforms are found in non-muscle cells (β- and γ1-cytoplasmic) and are ubiquitously 
expressed (Khaitlina, 2001). 
Actin exists as globular monomers called G-actin and as linear chains of G-actin 
subunits forming filamentous polymers called F-actin. These are about 8 nm in diameter 
and, being the thinnest of the cytoskeletal filaments, are also called microfilaments (or thin 
filaments in skeletal muscle fibers). The ability of G-actin to polymerize into F-actin and 
of F-actin to depolymerize into G-actin is an important property of actin and vital for 
several key cellular events such as cell motility, cell division, and endocytosis. Rapid 
polymerization and depolymerization of actin filaments occurs via binding and hydrolysis 
of ATP. Free actin monomers bind ATP and are incorporated onto the fast growing barbed 
end of the filament. ATP is then hydrolyzed to ADP and Pi. Dissociation of ADP-actin at 
the opposite pointed end causes disassembly of the filament. Actin treadmilling occurs 
when the association rate of free ATP-G-actin to the ends of actin filaments is balanced by 
the rate of subunit loss and no net growth occurs. Actin treadmilling is powered by ATP 
hydroylsis and this energy can be used to perform work (Pollard et al., 2000). 
The length of actin filaments is controlled by actin binding proteins (ABP). Capping 
proteins prevent assembly at the barbed end while ADF/cofilin binds to the side of ADP-
actin filaments to cause disassembly of the filament. In the absence of actin-binding 
proteins, the filament length is stable by the treadmilling mechanism. Profilin enhances 
filament assembly by promoting ADP to ATP exchange on actin and by directing actin 
monomers to the barbed end of filaments (Le Clainche et al., 2008). The Arp2/3 complex 
is involved in the organization of the actin network and it binds to the sides of existing 
filaments and initiates growth (nucleates) of new filaments creating a branched actin 
network (Small et al., 2002). 
In multicellular organisms, the actin cytoskeleton is required for several 
morphogenetic processes, such as movement of neurites during development, remodeling 
of the nervous system, and chemotactic movements of for example fibroblasts during 
wound healing. In muscle tissue, actin filaments participate in muscle contraction. Actin 
filaments are concentrated under the plasma membrane, where they form various 
structures that help cells to move. These protrusive structures of the plasma membrane are 
called lamellipodia or leading edge, filopodia, and pseudopodia. All of these structures 
contain different, specialized actin networks, depending on the accessory proteins 






Stress fibers are thick bundles of approximately 10-30 actin filaments traversing the 
cell (reviewed in Pellegrin et al., 2007, Naumanen et al., 2008). These bundles are held 
together by the actin-crosslinking protein α-actinin, although other actin-bundling 
proteins, such as fascin, espin and filamin, have also been detected in these regularly 
spaced thickenings called dense bodies. In addition to actin cross-linking proteins, the 
dense bodies are composed of scaffolding proteins and probably also transiently of 
proteins involved in signaling, such as kinases.  The staining pattern of α-actinin is 
periodic along the fiber and alternates with bands containing non-muscle myosin and 
tropomyosin. The stress fibers have the ability to contract and via adhesions transmit the 
generated energy to the extracellular matrix (ECM) and are thus suggested to resemble the 
sarcomeric actin filament structures of muscle cells. The contractile force of the stress 
fibers depends on the cellular needs. Tissue fibroblasts have sparse and poorly organized 
contractile actomyosin bundles, whereas smooth muscle cells are highly contractile cells 
with highly organized actomyosin arrays (Pellegrin et al., 2007). 
Stress fibers link the cell interior to the exterior through focal adhesions. Mammalian 
cells contain three categories of stress fibers: ventral stress fibers that are attached to focal 
adhesions at both ends, dorsal stress fibers that are attached to focal adhesions typically at 
one end and transverse arcs that are curved acto-myosin bundles, which do not directly 
attach to focal adhesions. Imaging of stress fiber formation in living cells shows that each 
type of stress fiber is assembled by a different mechanism (Hotulainen & Lappalainen, 
2006). 
The stress fibers are formed when physical stress is applied to the cells. Under normal 
conditions the three-dimensional ECM protects in vivo most cells against such forces, and 
only a few cell types including endothelial cells are under constant direct physical stress. 
When the support of the ECM is compromised, by a wound in the dermis for instance, the 
cells react rapidly to this new situation by forming stress fibers. Fibroblast cells cultured 
on artificial surfaces on tissue culture dishes develop also stress fibers while adapting to a 
two-dimensional growth environment (reviewed in Rönty, 2008). 
2. The muscle cell 
A contractile system involving actin and myosin is a basic feature of animal cells in 
general; however myofibrils of muscle cells display repeatable contraction and relaxation 
in a relatively short timescale. Cells specialized for contraction can be divided into skeletal 
muscle cells, cardiac muscle cells, smooth muscle cells, and myoepithelial cells. Skeletal 
and cardiac muscle cells appear striated, while smooth muscle and epithelial cells do not. 
Smooth muscles surround and control the involuntary movements of internal organs such 
as the large and small intestines, the blood vessels, and the uterus. Myoepithelial cells are 
found surrounding the secretory epithelium of glands or in the eye's iris (Reviewed in 






2.1. Striated muscle 
Each skeletal muscle cell (fiber) develops by the fusion of several muscle precursor cells 
with a single nucleus called myoblasts. Myoblasts proliferate extensively, but once they 
have fused, they can no longer divide. Fusion generally follows the onset of myoblast 
differentiation, in which genes encoding muscle-specific proteins are switched on 
coordinately. Once formed, a skeletal muscle fiber generally survives for the entire 
lifetime of the animal. Skeletal muscle fibers secrete myostatin to control their own 
growth. Some myoblasts persist in a quiescent state as satellite cells in adult muscle and 
can be reactivated to replace damaged muscle cells after injury (Lee & McPherron, 1999, 
Seale et al., 2000).  
Skeletal muscle is the most common type of muscle tissue in the body. It can be found 
in both slow and fast twitch forms. Fast twitch muscles can produce a burst of high energy 
for rapid and powerful movement, but they tire quickly. Their fibers are large in size and 
contain high glycogen storages and high glycolytic activity and narrow Z-disks. Slow 
twitch muscles produce less energy, but are designed for endurance and sustained work. 
They are richer in myoglobin, have high oxidative metabolism, and wide Z-disks (Luther 
et al., 2000).  
The skeletal muscles are voluntary muscles, which allow for the movement of bones 
and joints, while cardiac muscle cells, cardiomyocytes, are involuntary and found only in 
the heart. Both skeletal and cardiac muscles are striated muscles composed of thousands of 
contractile units known as sarcomeres. Each sarcomere is composed of repeated ordered 
arrays of thin and thick filaments, which give the muscle a striated appearance when it is 
viewed in an electron microscope. However, the organization in the cardiac muscle is not 
as regular as that in the skeletal muscle. Also other differences between cardiac and 
skeletal muscle occur. The cardiac muscle is made of single cells (cardiomyocytes), each 
with mainly one centrally located nucleus. The cardiac muscle is composed of branched 
muscle fibers, which are interlocked with those of adjacent fibers by adherens junctions. 
These strong mechanical attachments enable the heart to contract forcefully without 
ripping the fibers apart. Together with desmosomes, the adherens junctions bind together 
the cell membranes of two adjacent cells at the intercalated discs. These discs facilitate 
rapid communication, allowing the heart to coordinate muscular contractions (Gutstein et 
al., 2003, Perriard et al., 2003). Because of this anchoring property, the sarcolemmal 
adhesions represent the focal sites for bidirectional transmission of intrinsically cell-
generated and externally applied forces. For example, contracting adult rat cardiomyocytes 
plated on a laminin-coated silicone substrate produce pleat-like wrinkles on the substrate, 
which directly underlie the costameres (Danowski et al., 1992). Conversely, stretching rat 
cardiomyocytes end-to-end causes an immediate and homogenous increase in sarcomere 
length, indicating that externally applied strains are transmitted directly to the underlying 
contractile apparatus (Mansour et al., 2004). Cardiac muscle also differs from the other 
muscle types in that contraction can occur even without an initial nervous input. The cells 
that produce the stimulation for contraction without nervous input are called the 







Figure 1. Electron micrograph (upper) and schematic drawing of a sarcomere (lower). Thin 
filaments (chains of white round actin dots) are capped at the Z-disk by CapZ (yellow). 
Tropomyosin (black thread) and nebulin (red thread) filaments and troponin complexes (orange 
dots) are associated to the actin filaments. The Z-disk is composed of anti-parallel α-actinin 
molecules (dark green rods), myotilin (violet dot), FATZ (red rod), and myopalladin (pink 
triangle). The titin filament (violet thread) extends from Z-disk to M-line. At the Z-disk two titin 
filaments from opposed sarcomeres are cross-linked by telethonin (light green). The thick 
filaments are composed mainly of myosin (dark green). In the middle of the A-band, the M-line is 
composed of several proteins, among them M-protein (orange triangle), MURF-1 (light blue rod) 






2.2.  Sarcomere structure and function 
Apart from their role as force conduits, sarcolemmal adhesions initiate the assembly of 
sarcomeres. Sarcomerogenesis visualized in embryonic cardiomyocytes demonstrates that 
sarcomere precursors originate near the cell membrane at the sites of sarcolemmal 
adhesions (Du et al., 2008). Moreover, disruption of sarcolemmal adhesions results in loss 
of striated muscle organization, reduction of contraction, or cell death. 
The sarcomere is the contractile unit of striated muscle cells containing repeated 
ordered arrays of actin containing thin and myosin containing thick filaments. Muscles 
move when these filaments slide past each other. The force is generated by the myosin 
heads, which undergo an actin-activated ATPase cycle during which they form transient 
cross- bridges between thin filaments in the regions of overlap (reviewed by Geeves & 
Holmes, 1999).  
The sarcomere is divided into different bands or lines. A-bands span the length of thick 
filaments, while I-bands cover the area of thin filaments alone. The myosin part, which 
does not overlap with actin, is called the H-zone. The Z-disk (Z-line, Z-band) is the end of 
the sarcomere, where actin filaments from neighboring sarcomeres overlap and the M-line 
(M-region) is in the centre of the sarcomere, where thick filaments are cross-linked (Clark 
et al., 2002). The thick filaments are bipolar assemblies formed mainly from specific 
muscle isoforms of myosin II. Myosin binding proteins-C and -H contribute to the thick 
filament structure via interactions with myosin and titin in the A-band of the skeletal (-C 
and -H) and heart (-C) muscle sarcomere (Flashman et al., 2004). Myomesin, M-protein 
(or myomesin 2), and myomesin 3 are the main components of the M-band expressed in 
different muscle types. They bridge myosin filaments and anchor titin at the centre, 
creating a complex network of stabilizing interactions (Schoenauer et al., 2008). 
The Z-disks largely consist of α-actinin homodimers organized in an anti-parallel 
fashion and providing a backbone for the insertions of actin filaments, as well as nebulin 
and titin. Titin forms a continuous filament system in the myofibrils, with single 
molecules spanning from the Z-disk to the M-band in both skeletal muscle and heart 
(Tskhovrebova et al., 2010). Different isoforms of the largest protein (3.0–3.7 MDa) vary 
in the size and structure of the elastic I-band part of the molecule. The size and structure of 
the thick filament part of titin is conserved, which is consistent with the conserved 
structure of thick filaments in vertebrates. Titin’s N-terminus is coupled via telethonin (T-
cap) to muscle LIM protein (MLP), which is believed to be central to Z-disk-based 
mechanosensing (Knöll et al., 2002). Because A-band titin provides regularly spaced 
binding sites for myosin and myosin binding protein C, it may function as a molecular 
ruler that controls assembly and length of the thick filament. Titin consists mainly of about 
300 immunoglobulin (Ig) and fibronectin (Fn) domains that give to the entire protein a 
“beads-on-the-string” appearance (Labeit & Kolmerer, 1995). A unique region with 
spring-like properties, designated the PEVK segment confers elasticity to the entire 
molecule. Due to the PEVK region, titin behaves like an extensible spring (Linke et al., 
2002). The M-line region of titin contains a serine/threonine kinase domain that has been 
shown to phosphorylate the Z-disk protein telethonin probably regulating myofibril 






sarcomere development, specifically, integration of titin in the A band and sarcomere 
structure maintenance.  It has also been proposed that titin kinase is a mechanosensor that 
regulates muscle protein expression in a strain-dependent fashion. Titin kinase has also 
been proposed to assemble an nbr1-based signalosome that communicates with the 
nucleus and modulates, in a stretch-dependent manner, protein expression and turnover 
(Lange et al., 2005). Finally, recent studies suggest that titin kinase affects cardiac 
contractility owing to decreased sarcoplasmic reticulum calcium uptake (LeWinter et al., 
2010). Titin binds several proteins that have diverse roles in sarcomeric structure, protein 
turnover, biomechanical sensing, and signaling. This suggests that titin has complex and 
important integrative functions, represented diversely in the different isoforms. 
Titin and nebulin together specify Z-disk width, with titin constructing the central 
region of the Z-disk, including the number and positions of α-actinin cross-links and 
nebulin beeing a Z-disk terminator determining the ending of the Z-disk structure and its 
transition to the I-band. Nebulin is also a giant protein (500-900 kDa). A single nebulin 
molecule spans the thin filament with its C-terminus anchored at the Z-disk and its N-
terminal region directed towards the thin filament pointed end (Labeit & Kolmerer, 1995). 
It consists of 185 repeated domains arranged into super repeats. This precise arrangement 
is thought to allow each central nebulin module (M9-M162) to interact with a single 
monomer of the actin filament (Labeit & Kolmerer, 1995), and each nebulin super-repeat 
to associate with a single tropomyosin (Tm)/troponin (Tn) complex. Nebulin’s extreme N-
terminal modules M1–M3 contain a high-affinity binding site for the thin filament 
pointed-end capping protein tropomodulin (McElhinny et al., 2003). Tropomodulin, in 
addition to binding nebulin's N-terminus, binds actin and tropomyosin with high affinity 
and prevents actin filaments from elongating or shortening at the pointed end (dos 
Remedios et al., 2003). Nebulin plays a critical role in regulating thin filament length, 
since in its absence in knock out mice the average thin filament length is shorter and force 
is greatly reduced (Bang et al., 2006, Witt et al., 2006).  
In the transverse direction, linkage of myofibrils at the Z-disks allows for lateral force 
transmission and limits the degree to which adjacent myofibrils translocate relative to each 
other during active contraction or passive stretch, thereby preventing damage to inter-
myofibrillar membrane systems, such as T-tubules and the sarcoplasmic reticulum. The 
intermediate filaments are thought be one of the major elements responsible for 
maintaining the highly ordered myofibrillar alignment of striated muscle and for the 
precise positioning of intracellular organelles within the myofiber. Desmin intermediate 
filaments link Z-disks of adjacent myofibrils with the plasma membrane (sarcolemma) and 
other organelles within the cell (mitochondria and nuclei). The attachment of the 
sarcomeres to the sarcolemma occurs at the costameres, sub-sarcolemmal cytoskeletal 
complexes aligned with the Z-disk and M-line (Clark et al., 2002).  
The subunit proteins of desmin filaments are elongated coiled-coils with extensive 
intermolecular ionic and hydrophobic interactions between individual subunits, giving rise 
to filaments with high tensile strength as well as plasticity. Nebulin is required to laterally 
link myofibrils at the Z-disk by desmin filaments; in the absence of nebulin myofibrillar 
connectivity is significantly reduced leading to Z-disk displacement (Bang et al., 2002). In 






mechanism by which nebulin terminates the Z-disk might involve interaction between 
nebulin and Z-disk-localized CapZ. CapZ is a barbed-end actin-capping protein that binds 
near the C-terminus of nebulin (Pappas et al., 2008). When these structural functions of 
nebulin are absent, muscle weakness ensues, as is the case in patients with nemaline 
myopathy with mutations in nebulin. In addition to the structural roles, nebulin may 
control contraction by controlling access of myosin heads to the actin filaments and 
participate in signal transduction (Ma et al., 2002), and be involved in physiological 
calcium handling of the sarcoplasmic reticulum-myofibrillar system (Ottenheijm et al., 
2008).  
Nebulette is a smaller, cardiac-specific nebulin homologue. Similar to nebulin, 
nebulette binds actin, myopalladin, and tropomyosin and is critical for thin filament 
assembly, their spatial organization and the contractile activity. In addition, nebulette 
interacts with the Z-disk proteins ZASP and filamin C (Holmes et al., 2008).  
The filamins are a family of high molecular mass cytoskeletal proteins that organize 
filamentous actin into networks. The human filamins consist of 3 isoforms, filamins A, B, 
and C, which share approximately 70% sequence homology. The significance of filamins 
A and B in human biology was identified in genetic diseases affecting the brain, bone, and 
cardiovascular system (Krakow et al., 2004). Filamin C is predominantly expressed in 
skeletal muscle cells, where localizes at the myofibrillar Z-disk, by binding to myotilin, 
FATZ, and myopodin, an F-actin-binding protein that was initially reported to be 
significantly downregulated in Duchenne muscular dystrophy (van der Ven et al., 2000, 
Faulkner et al., 2000, Linnemann et al., 2010), and at the sarcolemma by interacting with 
γ- and δ-sarcoglycans (Thompson et al., 2000). Therefore, it provides a direct link between 
the sarcolemma and the myofibrils and is thought to have an important function in 
signaling between the two compartments. Filamin C plays an important role in early 
muscle development and stabilization of the myofibrillar Z-disk (van der Ven et al., 2000, 
Dalkilic et al., 2006). 
2.3. Myotilin/palladin/myopalladin protein family 
2.3.1. Myotilin 
Myotilin, the main subject of this dissertation, is a 57 kDa protein consisting of two Ig 
domains flanked by a unique serine-rich N-terminus and a short C-terminal tail 
(Salmikangas et al., 1999). On the basis of similarities in sequences and structure, the 
protein domains that form the immunoglobulin super family have been divided into V, C1, 
C2, and I sets. These differ from one another with respect to edge strands on each beta 
sheet, in how far strands extend toward the “top” of the domain relative to the cysteines in 
the B and F strands, and with respect to certain framework residues (Harpaz & Chothia, 
1994). The Ig domains of myotilin, locating at amino acids 252-341 and 351-441, were 
predicted by sequence comparison to fold into seven β-sheets and to fall into the category 






determined with solution state NMR spectroscopy exhibits, however, the I-type of Ig-fold, 
being intermediate between the V and C type (Heikkinen et al., 2009). I-type fold is also 
seen in the structures of palladin Ig-domains 1 and 2, which are available in the PDB 
database (PDB accession codes 2DM2 and 2DM3). According to structural similarity 
search on DALI server the five closest structures to myotilin Ig1 are found in titin, aortic 
preferentially expressed protein-1, telokin, palladin, and myomesin. These all are clearly I-
type Ig-domains (Heikkinen et al., 2009). 
Similar Ig domains are found mainly in sarcomeric proteins such as titin, filamin C, 
myomesin, M-protein, MyBP-C, myopalladin and palladin (Vinkenmeyer et al., 1993, 
Labeit and Kolmerer, 1995, Vaughan et al., 1993, Bang et al., 2001, Rönty et al., 2004). 
Most of these proteins have significant links to human disease (reviewed by Otey, 2009) 
and certain inherited forms of heart disease are associated with mutations affecting the Ig 
domains of either MyBP-C or titin, which suggests that Ig domains have a key role in 
maintaining sarcomere integrity (Watkins et al., 1995, Gerull et al., 2002, Gerull et al., 
2006). By sequence comparison, the Ig domains of myotilin are most homologous to Ig 
domains 2 and 3 of palladin 90-92 kDa isofoform (Parast & Otey, 2000, Mykkänen et al., 
2001) and Ig domains 4 and 5 of myopalladin (Bang et al., 2001). Together, these three 
proteins form a subfamily of actin-associated proteins. Ig-domains are important for 
protein-protein interactions and the Ig-domain-containing region in myotilin interacts with 
N-terminus of the Z-line protein filamin C (van der Ven et al., 2000) and the C-terminus 
of myotilin makes homodimers in solution. Results obtained from cell transfection 
experiments suggest that myotilin’s Ig domains also participate in F-actin organization 
(Salmikangas et al., 2003).  
Myotilin (myofibrillar titin-like protein) was originally identified as a binding partner 
for α-actinin in a yeast two-hybrid screen. The proteins co-localize at the sarcomeric Z-
disks (Salmikangas et al., 2003) by interaction between myotilin’s amino terminal region 
(amino acids 79–125) and the C-terminal EF-hand repeats 3 and 4 of α-actinin (Hauser et 
al., 2000, A. Taivainen, M. Rönty, O. Carpén, unpublished data). Myotlin binds also 
directly to the Z-disk proteins FATZ-1, FATZ-2 (Gontier et al., 2005), and telethonin 
(Suila, H.2006 ASCB annual meeting B190). 
Myotilin binds F-actin directly at a 1:1 ratio and cross-links actin filaments into large 
stable bundles in vitro. In cultured cells, expression of myotilin results in a unique 
phenotype with a network of filaments consisting of F-actin and myotilin (Salmikangas et 
al., 2003). Furthermore, forced expression of myotilin in early times of muscle cell 
development leads to strong actin bundle formation, which prevents normal assembly of 
sarcomeres (Salmikangas et al., 2003). These actin-regulating properties of myotilin are 
rather unique, and suggest that myotilin may play a role in sarcomere organization. In 
addition, mutations in the myotilin gene (MYOT) can cause different forms of muscle 
disease, characterised clinically by progressive muscle weakness and sarcomeric disarray.  
The myotilin gene is located on chromosome 5q31 and the coding sequence is 
composed of 10 exons. Myotilin is mainly expressed in adult striated muscles and nerves 
(Salmikangas et al., 1999), but low levels of myotilin are also detected in other tissues 
(Godley et al., 1999). In mouse and human embryos, myotilin is expressed in lung, liver, 






myotilin is predominantly found within the Z-disks, although it has been observed in the 
sarcolemma as well, which could be explained by the interaction with filamins providing a 
link between the cell membrane and the sarcolemma (Salmikangas et al., 1999, van der 
Ven et al., 2000, Gontier et al., 2005). The expression of myotilin begins at late stages of 
muscle cell differentiation, after expression of titin and other sarcomeric proteins, 
suggesting that myotilin is involved in the final alignment of myofibrils rather than in 
initial assembly of the Z-disk. Myotilin is highly conserved and similarly regulated 
between human and mouse (Mologni et al., 2005). The coding sequences of the myotilin 
gene are 80% identical and amino acid sequences show 90% identity (Mologni et al., 
2001). The human myotilin polypeptide consists of 498 amino acids and the mouse 
ortholog of 496 amino acids.  
Myotilin’s roles in normal mammalian development and physiology remain somewhat 
undefined. The widespread developmental expression of myotilin suggests a relevant role 
in mouse development. Mutations in the human myotilin gene have also been implicated 
in three different muscle disorders, suggesting that expression of wild-type myotilin would 
be required for normal muscle development in mammals. Surprisingly, conditional 
myotilin knockout mice are born at normal mendelian ratio and appears healthy 
throughout their lives. A thorough analysis has not revealed any abnormalities in 
sarcomeric structure in either embryonic or adult mice, and neither muscle strength nor 
muscle performance is affected in the mice (Moza et al., 2007). Since myotilin is closely 
related to palladin and myopalladin, it is possible that these family members compensate 
for the absence of myotilin in the knockout mice. Even double mutant myotilin-
null/200kDa-palladin-hypomorph mice do only develop a mild myopathy at old age 
(Moza, 2008). It may be necessary to develop a muscle-specific triple 
myotilin/palladin/myopalladin knockout mouse to understand myotilin’s role in muscle 
development. 
Whereas myotilin knockout mice are virtually normal, mice with introduced 
myotilinopathy patient mutations develop progressive myofibrillar pathology, indicating 
that dysfunctional myotilin is more harmful to muscle cells than loss of the protein. A 
transgenic mouse model expressing human myotilin carrying a myotilinopathy associated 
mutation T57I reproduces many of the symptoms and pathology associated with the 
myotilinopathies—Z-disk streaming, myofibrillar aggregation and muscle weakness. 
Centrally located nuclei are also observed, indicating regeneration and replacement of 
damaged myofibres. Protein aggregates derived from degenerating myofibrils reminds of 
the pattern found in myotilinopathy patients. The aggregates contain α-actinin, filamin C, 
desmin, titin and myosin and also transgenic myotilin (Garvey et al., 2006). Compared to 
single-transgenic mutant mice, double-transgenic mice overexpressing myotilin showed 
more severe muscle degeneration, enhanced myofibrillar aggregation, and earlier onset of 
aggregation (Garvey et al., 2008). These data suggest that strategies aimed at lowering 
total myotilin levels in myotilinopathy patients may be an effective therapeutic approach. 
In non-diseased muscle affected by eccentric exercise myotilin is present in increased 
amount in lesions related to Z-disk streaming and events leading to insertion of new 
sarcomeres in pre-existing myofibrils and can therefore be used as a marker for 






rather than with the core Z-disk protein α-actinin during these events, suggesting that 
myotilin has a key role in the dynamic molecular events mediating myofibrillar assembly 
(Carlsson et al., 2007). 
 
Figure 2. Domain organization of myotilin, reported myotilinopathy mutations, and 
interactions. The molecule consists of a serine-rich region (grey box) containing a hydrophobic 
stretch (black box) followed by two Ig domains and a C-terminal tail. Reported myotilinopathy 
mutations are shown on top and regions of interaction with different interaction partners below. 
Interactions reported in this study are shown in grey. 
2.3.2. Palladin 
Palladin can be described as an actin-binding molecular scaffold that forms complexes 
with a wide variety of cytoskeletal regulators. It was the second myotilin-palladin-
myopalladin family member to be characterized, independently by three research groups 
(Parast & Otey, 2000, Liu et al., 2000, Mykkänen et al., 2001). In contrast to myotilin and 
myopalladin that are expressed predominantly in striated mucle, palladin is expressed in 
both muscle and nonmuscle cell types, and is especially abundant in embryos and 






Palladin exists as multiple isoforms that arise from a single gene highly conserved 
between vertebrate species. Originally, three major isoforms (90 - 92, 140, and 200 kDa) 
were described, and these are transcribed from different promotors (Parast & Otey, 2000, 
Rachlin & Otey, 2006). Recently, up to fourteen potential isoforms have been annotated 
by various transcriptome databases (Otey et al., 2009). The high degree of isoform 
variability and tissue specific expression of isoforms suggest that different palladin 
variants may be specialized for different functions. The 90 - 92 kDa palladin doublet is the 
most widely expressed isoform, being essentially ubiquitous in developing mouse organs 
(Parast & Otey, 2000, Wang & Moser, 2008). Also the 140 kDa palladin is widely 
expressed, although it is not detected in several major organs such as liver, muscle and 
skin, while the 200 kDa isoform has been detected mostly in heart, skeletal muscle, testis, 
and bone (Rachlin & Otey, 2006, Wang & Moser, 2008). All palladin isoforms described 
contain from one to five Ig domains. The largest 200 kDa palladin isoform has two amino 
terminal and three carboxy terminal Ig domains, the 140 kDa variant has one N-terminal 
and three C-terminal Ig domains, and the smallest, most common 90-92 kDa isoform has 
three C-terminal Ig domains. The C-terminal Ig domains of palladin bind ezrin, a member 
of the ezrin-radixin-moesin family of scaffold proteins (Mykkänen et al., 2001) and bind 
and crosslink actin filaments (Dixon et al., 2008). 
In addition to the Ig-domains, two proline-rich (PR) domains of palladin play 
important roles in its molecular binding interactions. The 90 - 92 kDa isoform has one PR 
domain, The 140 and 200 kDa isoforms two, that are located between the second and the 
third Ig domains of the 200 kDa isoform. Palladin’s PR domains bind to Lasp-1, an actin-
binding protein from the nebulin/nebulette family (Rachlin & Otey, 2006). Lasp-1 
expression is required for normal cell migration, and misregulated Lasp-1 has been 
implicated in the motility of ovarian cancer and breast cancer cells (Lin et al., 2004, 
Grunewald et al., 2006, Grunewald et al., 2007). The PR domains of palladin interact also 
with the actin-regulating proteins VASP (and its relatives Mena, Ena, and EVL), profilin 
and Eps8 (Boukhelifa et al., 2004, Boukhelifa et al., 2006, Goicoechea et al., 2006). VASP 
and its relatives play important roles in actin cross-linking, regulating actin filament 
growth and cell motility (Boukhelifa et al., 2004). VASP forms complexes with profilin, 
suggesting that palladin and VASP may function together to recruit profilin to sites of 
actin polymerization (Boukhelifa et al., 2006). Eps8 plays a critical role in regulating the 
length of actin filaments, is involved in motility of invasive cancer cells, and is a substrate 
for the EGF receptor and many other tyrosine kinases (Goicoechea et al., 2006).  
In addition, palladin’s PR region binds to signaling intermediaries such as ArgBP-2 
and SPIN-90 (Rönty et al., 2005, Rönty et al., 2007). Other interaction partners involved 
in signaling are Src, a key player in podosome formation (Rönty et al., 2007) and Akt-1 
that mediates inhibition of breast cancer cell migration (Chin & Toker, 2010).  
Like the other family members, palladin binds to α-actinin, a widely expressed actin-
crosslinking protein, which docks in the region between PR2 and Ig-3 (Rönty et al., 2004). 
This binding sequence is highly conserved also in myotilin. Alpha-actinin is a member of 
the spectrin/dystrophin family, and it is ubiquitously expressed in vertebrate cells. Palladin 
co-localizes with α-actinin in focal adhesions, cell-cell junctions and stress fibres. In 






interacts with multiple transmembrane and signaling proteins (Otey & Carpen, 2004). 
Recently, palladin was shown to bind CLP36, mystique, and RIL, members of the alpha-
actinin-associated LIM protein (ALP)/enigma protein family (Zheng et al., 2009, 
Hasegawa et al., 2010). Taken together, the diversity of palladin-binding partners suggests 
that palladin regulates the organization of the actin cytoskeleton via multiple molecular 
pathways. 
In addition to being a molecular scaffold, palladin plays a role in cell motility, 
embryonic development, wound healing, and in invasive cancer (Goicoechea et al., 2008). 
Knockout of palladin in mice is embryonic lethal, demonstrating the importance of 
palladin in development (Luo et al., 2005). Mice with reduced muscle specific palladin 
200 kDa isoform expression developed ultrastructural modifications in cardiomyocytes, 
but no skeletal muscle defects (Moza, 2008).  
Mutations in the palladin gene (PALLD) have been connected to familial pancreatic 
cancer resulting from a single amino acid substitution at the α-actinin binding site (Pogue-
Geile et al., 2006), although this finding has later been challenged (Zogopoulos et al., 
2007). Palladin has also a connection to breast cancer, where palladin levels correlate with 
increased invasiveness (Wang et al., 2004).  
2.3.3. Myopalladin 
Myopalladin is the third member of the myotilin-palladin-myopalladin family and 
contains five Ig domains. Myopalladin’s diverse molecular interactions suggest that it may 
be involved in both the structural aspects of sarcomere assembly and in regulation of 
sarcomeric gene expression. Myopalladin binds to nebulin and its relative nebulette. By its 
C-terminal region containing Ig domains, myopalladin binds to α-actinin and by its two 
N-terminal Ig-domain-region to the cardiac ankyrin repeat protein CARP (Bang et al., 
2001). CARP localizes largely to the nucleus, where it regulates the expression of cardiac 
genes, and in the sarcomeric I-band. CARP is abundantly expressed in the developing 
heart and is strongly induced in cardiac hyperthrophy or stressed skeletal muscle (Aihara 
et al., 2000). Missense mutations in genes encoding for both CARP and myopalladin are 
associated with dilated cardiomyopathy (DCM) (Duboscq-Bidot et al., 2009, Duboscq-
Bidot et al., 2008). In the myopalldin gene (MYPN), four independent missense mutations 
have been found to be responsible for DCM, suggesting that myopalladin plays a 
significant role in normal cardiac physiology. Three of the mutations are located in the C-
terminal Ig domains of myopalladin and one of them, located in the fourth Ig domain, is 
associated with decreased localization to the Z-band area of left ventricular cardiac 
myofibrils (Duboscq-Bidot et al., 2008). 
2.4. FATZ proteins 
The FATZ (calsarcin, myozenin) proteins form another Z-disk family with structural and 






FATZ-2 (calsarcin-1, myozenin-2), and FATZ-3 (calsarcin-3, myozenin-3) are localized in 
the Z-disk binding not only to myotilin but also to the filamins A, B, and C (Gontier et al., 
2005), telethonin (T-cap), α-actinin, ZASP (cypher/oracle), and calcineurin (Faulkner et 
al., 2000; Frey et al., 2000; Frey & Olson, 2002; Takada et al., 2001). While FATZ-1 and 
FATZ-2 are expressed both in skeletal muscle and heart, FATZ-3 appears restricted to the 
skeletal muscle. The three proteins share high homology both at the N- and the C-terminal 
regions and in fact the binding sites for a variety of proteins occur in these areas. It has 
been suggested that the FATZ family may play a role in contributing to the formation and 
maintenance of the Z-disk (Frey & Olson, 2002) as well as in cell signaling since the 
members bind to calcineurin. Muscle cells are able to sense changes in their workload and 
adapt accordingly via complex signaling pathways, some involving calcium as its level in 
the muscle cells alters in response to the nerve pulses and muscle contraction. As a 
response to stress, muscle fibers hypertrophy, and become more efficient, shifting towards 
a slow fiber-type. Calcineurin is a sarcomeric calcium/calmodulin dependent phosphatase 
that could act as a sensor of change and is involved in the regulation of genes affecting 
muscle differentiation and fiber-type specification (Frey & Olson, 2002). FATZ-1 and 
FATZ-3 are highly expressed in skeletal muscle fast-twitch fibers, while FATZ-2 is highly 
expressed in cardiac muscle slow-twitch fibers. Mice lacking FATZ-2 show an increase in 
calcineurin activity and a concurrent increase in the percentage of slow-twitch fibers (Frey 
et al., 2004). Mutations in FATZ-2 are associated with hypertrophic cardiomyopathy 
(Osio et al., 2007). 
2.5. PDZ-LIM domain proteins 
Characterized by their Postsynaptic density 95, discs large and zonula occludens-1 (PDZ) 
and Lin-11, Isl1 and Mec-3 (LIM) domains, the PDZ-LIM family is comprised of 
evolutionarily conserved proteins found throughout the animal kingdom, from worms to 
humans. PDZ and LIM domains act as scaffolds, binding to filamentous actin-associated 
proteins, a range of cytoplasmic signaling molecules, and nuclear proteins during 
development and homeostasis (Krcmery et al., 2010). 
PDZ domains are structurally conserved 80-100 amino acid modules being present 
singly or in multiple repeated copies in a diverse set of proteins.  In most cases, they 
recognize C-terminal sequence motifs of target proteins and bind these peptides in a 
pocket between a β strand and an α helix (Harris & Lim, 2001). A given PDZ domain can 
interact with several targets. Similarly, a given PDZ binding motif of 3-7 amino acids can 
bind to several PDZ domains. 
A classification of PDZ-binding motifs in the C-terminus has been used, in which the 
consensus sequence for type I is S/T-X-hydrophobic-COOH, and for class II is 
hydrophobic-X-hydrophobic-COOH (Songyang et al., 1997). More recently new PDZ-
binding motifs, which do not belong to either of the two classes, have been discovered and 
it has become apparent that residues further N-terminal are important for specificity as 






motifs seem to be needed since as many as 545 PDZ domains in 343 proteins are 
estimated (Zimmermann et al., 2006). 
LIM domains can be found internally as well as near the N- or C-terminal regions of 
LIM domain proteins. The LIM domains are 50–60 amino acids in size and share two 
characteristic zinc finger folds, which are separated by two amino acids. The two zinc 
fingers that constitute a LIM domain contain eight conserved residues, mostly cysteines 
and histidines, which coordinately bond to two zinc atoms (Zheng et al., 2007). 
There are seven PDZ-LIM proteins: PDLIM1/CLP36/ CLIM1/Elfin, 
PDLIM2/Mystique/SLIM, PDLIM3/ALP, PDLM4/RIL, PDLIM5/ENH, 
PDLIM6/LDB3/ZASP/Cypher, and PDLIM7/Enigma/LMP-1, the prototype of enigma 
gene family (reviewed by Zheng et al., 2009). They all localize to actin stress fibers or the 
muscle Z-disk. They have an N-terminal PDZ domain and one (ALP, RIL, CLP-36) or 
three (Enigma, ENH, ZASP/Cypher1) C-terminal LIM domains. PDZ-LIM proteins 
associate mainly with the actin cytoskeleton via their PDZ domain and with kinases via 
their LIM domain. The PDZ domains of many, if not all, of these proteins interact with the 
C-terminal peptide of α-actinin. In addition, ALP, ZASP/Cypher and CLP36 interact with 
the α-actinin rod domain via sequences located between the PDZ and LIM domains, 
mapping close to a conserved 26 amino acid motif, the ZM motif, found in these three 
proteins (Klaavuniemi & Ylänne, 2006). ALP, ENH and ZASP show high expression in 
muscle tissue, and CLP36 and RIL are expressed in various tissues, with high expression 
observed in epithelial cells (Vallenius et al., 2004). In muscle, PDZ-LIM proteins function 
as adaptors in translating mechanical stress signals from the Z-disk to the nucleus 
(Hoshijima 2006). 
2.5.1. ZASP 
Z band alternately spliced PDZ-containing protein (ZASP also named LIM domain-
binding factor 3, Cypher, or Oracle) is a Z-disk-related cytoskeletal protein expressed in 
the striated muscles. Three groups found it independently in cardiomyocytes. The human 
and mouse sequences of ZASP were found by Faulkner’s laboratory and named as Z band 
alternatively spliced PDZ-motif protein (Faulkner et al., 1999), Chen’s laboratory 
identified splicing variants of mouse homologs of ZASP by in silico screening of LIM 
proteins enriched in the heart and named this gene as Cypher (Zhou et al., 1999), and 
Olson’s group isolated mouse sequence of ZASP, named Oracle, during their process of 
differential screening of genes expressed specifically in the heart (Passier et al., 2000). 
There are several ZASP isoforms, all of which have an amino terminal PDZ domain 
required for binding α-actinin while the longer isoforms have LIM domains at the carboxy 
terminus involved in the binding PKCs (Zhou et al., 1999). This domain mediates 
interaction with ZASP in a phosphorylation-dependent manner and is involved in the 
targeting of ZASP. In mouse, six splice variants of ZASP/Cypher have been characterized, 
which fall into two classes, one specific to cardiac and the other predominant in skeletal 
muscle (Huang et al., 2003). These isoforms include short (Cypher2c, 2s) and long 






splice variants of Cypher/ZASP have been identified, with one long and one short isoform 
specific to cardiac or predominant in skeletal muscle, respectively (Faulkner et al., 1999; 
Vatta et al., 2003). 
ZASP knockout mice display a severe form of congenital myopathy and die 
postnatally (Zhou et al., 2001) and although ZASP is not required for Z-disk assembly it is 
required for the maintenance of the Z-disk during muscle function. Cardiac-specific ZASP 
knockout mice develop a severe form of DCM with disrupted cardiomyocyte 
ultrastructure and decreased cardiac function, which eventually lead to death before 23 
weeks of age. A similar phenotype is observed in inducible cardiac-specific ZASP 
knockout mice in which ZASP is specifically ablated in adult myocardium. In the cardiac-
specific knockout models, ERK and Stat3 signaling is increased (Zheng et al., 2009).  In 
humans, ZASP is linked with dominant familial dilated cardiomyopathy (Vatta et al., 
2003). An Asp626Asn mutation was demonstrated to increase the affinity of ZASP to 
PKC (Arimura et al., 2004) suggesting a disturbance of the adaptor function of ZASP for 
PKC may play a role in the pathogenesis of a subset of dilated cardiomyopathy. In 
addition to its association with DCM, mutations in ZASP result in myofibrillar myopathy 
(MFM) (Selcen & Engel, 2005; Vorgerd et al., 2005, Griggs et al., 2007). 
2.5.2. ALP 
The 36 kDa actinin-associated LIM protein (ALP, also known as PDZ and LIM domain 
protein 3 or PDLIM3) has an N-terminal PDZ domain and a single LIM domain at the C-
terminus. Four ALP proteins have been identified in mammals, each having multiple 
splice variants and unique expression patterns (Zheng et al., 2010). ALP interacts directly 
with α-actinin and is co-localized with α-actinin at the Z-disks in cardiac or skeletal 
muscle (Xia et al., 1997), however, ALP localization at the Z-disk is independent of its 
association with α-actinin (Henderson et al., 2003). In fact, ALP is more readily detectable 
at the intercalated disks in adult mouse hearts in a distribution that does not overlap with 
α-actinin in cardiomyocytes (Pashmforoush et al., 2001). ALP is expressed in smooth, 
cardiac, and skeletal muscle cells and dramatically up regulated in differentiated smooth 
and skeletal muscle (Pomies et al., 1999 and Xia et al., 1997). 
Mice that lack ALP develop right ventricular dysplasia and a mild right ventricular 
cardiomyopathy (Lorenzen-Schmidt et al., 2005, Lorenzen-Schmidt et al., 2000, 
Pashmforoush et al., 2001). ALP enhances the ability of α-actinin to crosslink actin 
filaments, indicating that ALP stabilizes actin filament anchorage at Z-lines and 
intercalated discs in cardiac muscle (Pashmforoush et al., 2001). Knockdown of ALP 
expression affects the expression of the muscle transcription factors Myogenin and MyoD, 
resulting in the inhibition of muscle differentiation (Pomies et al., 2007). These studies 
suggest that ALP plays a critical role in the integration of cytoskeletal architecture and 






2.5.3. CLP36 and RIL 
At the stress fibers, sarcomere-like structures in non-muscle cells with several shared 
components including myosin, tropomyosin, titin and α-actinin, 36 kDa C-terminal LIM 
domain protein (CLP36 also called CLIM1, Elfin, PDLIM1) and RIL (PDLIM4) bind α-
actinin (Vallenius et al., 2004). CLP36 and RIL are mostly expressed in epithelial tissues 
and CLP-36 also in heart (Cuppen et al., 1998; Kiess et al., 1995; Vallenius et al., 2000, 
Vallenius et al., 2004). The comparison of Clp36 and Ril expression patterns reveals that 
although they both are expressed in several epithelial tissues, the expression patterns do 
not overlap considerably, suggesting that they might have separate functions in cells 
(Vallenius et al., 2004). Both proteins have a PDZ domain at their N-terminal and a LIM 
domain at their C-terminal regions. 
CLP36 associates with α-actinin 1 and α-actinin 4 at stress fibers in non-muscle cells 
(Vallenius et al., 2000) and with α-actinin 2 at the Z-lines in myocardium (Kotaka et al., 
1999, 2000). CLP36 associates with Clik1, which is a serine/threonine protein kinase and 
is important for the localization of Clik1 to actin stress fibers (Vallenius & Mäkelä, 2002). 
CLP36 is also required for the organization of stress fibers and focal adhesions of BeWo 
(choriocarcinoma) cells (Tamura et al., 2007). 
Ril was initially identified as a gene down-regulated in H-Ras transformed cells (Kiess 
et al., 1995), and RIL was shown to associate with the protein tyrosine phosphatase PTP-
BL phosphatase via its LIM domain (Cuppen et al., 1998). Moreover, RIL interacts with 
the AMPA glutamate receptor in dendritic spines through the C-terminal LIM domain 
(Schulz et al., 2004). RIL homodimerizes through LIM-PDZ interactions (Cuppen et al., 
1998), associates with α-actinin via its PDZ domain and enhances the ability of α-actinin 
to cross link F-actin. RIL over expression in cells leads to partially abnormal actin 
filaments showing thick irregular stress fibers not seen with CLP-36 and live cell imaging 
demonstrates altered stress fiber dynamics with rapid formation of new fibers and frequent 
collapse of thick irregular fibers in EGFP-RIL-expressing cells. These results implicate 
the RIL PDZ-LIM protein as a regulator of actin stress fiber turn over (Vallenius et al., 
2004).  
2.6. Sarcomere turnover and adaptation 
During the continuous contraction of the muscle sarcomere, new proteins are exchanged 
into the structure via a carefully orchestrated process of synthesis and degradation. This 
continual remodeling allows adaptation to stress, including exercise, metabolic influences, 
or disuse and must occur without affecting the integrity of the contractile force necessary 
for the muscle to continue to function. 
Striated muscle cells are almost crystalline in architecture and it is difficult to see how 
new elements might be added in a mature fiber under the constraint of continued force 
production by the muscle. Therefore, models of de novo sarcomere formation that follow 
the sequential assembly process of premyofibril formation initiated at the cell membrane 






encountered in the body during adaptation to hemodynamic loads. Furthermore, sarcomere 
addition may proceed in either a longitudinal or transverse direction to regulate cell shape 
and function (reviewed in Russell et al., 2010). 
Adult skeletal muscle is thought to lengthen mainly by the addition of new sarcomeres 
at the ends of the fibers near myotendon junctions (Dix et al., 1990). Fibers do not end at 
flat transverse discs, but at very irregular structures with some sarcomeres seen to creep 
ahead of others perhaps used to elongate the cell. The analogous terminal structure in the 
heart cell is the intercalated disc where force is transmitted longitudinally through very 
strong adherens junctions. Intercalated discs are even more irregular in cardiac 
hypertrophy and have a denser architecture in myopathic hearts (Perriard et al., 2003). 
New sarcomeres can also be added in the middle of the fiber as shown in human 
skeletal muscle where a Y-shaped scaffold projects inwards from the membrane to splice 
in new, shorter sarcomeres at the Z-disk in a desmin-labeled zone (Yu & Russell, 2005). 
The role of a Y-scaffold for sarcomeric addition was also confirmed in cardiac myocytes 
during rapid lengthening in culture (Yu & Russell, 2005). 
It is also possible that actin filaments and sarcomeres can be added internally well 
away from the membrane (Carlsson et al., 2007). The contractile material in striated 
muscle is thought by many to remodel using the Z-disk, which is a transversely oriented, 
lateral extension of the focal adhesion. Thus, Z-disks may act as a platform for actin 
filament polymerization internally in addition to the membrane location. Unfortunately 
this perpendicular structure is missing in conventional flat 2D cultures and its absence 
might explain slow progress in our understanding of myocyte width regulation. Hopefully 
this will be accelerated now with better 3D models in culture (Senyo et al., 2007) and from 
the zebrafish studies of Sanger and others (2009). 
Factors that play a role in the regulation of protein quality control in the sarcomere 
include chaperones that mediate the assembly of sarcomere components and ubiquitin 
ligases that control their specific degradation. The co-chaperones UNC-45, Hsp90, and 
Hsp70 are required for the assembly of myosin and desmin assembly requires αB-
crystallin (Barral & Epstein, 1999, Liu et al., 2008, Bar et al., 2004). There is clear 
evidence of sarcomere disorganization in animal models lacking muscle-specific 
chaperone proteins, illustrating the importance of these molecules in sarcomere structure 
and function. Furthermore, mutations in either desmin or αB-crystallin are the cause of 
numerous pathologies (Bar et al., 2004, Selcen 2010).  
The dynamic interplay between sarcomere-specific chaperones and degradation of 
sarcomere proteins is necessary in order to maintain structure and function of the 
sarcomere. Muscle contains four proteolytic systems in amounts such that they could be 
involved in metabolic protein turnover: 1) the lysosomal system, 2) the caspase system, 3) 
the calpain system, and 4) the proteasome (reviewed in Goll et al., 2008). The catheptic 
proteases in lysosomes are not active at the neutral pH of the cell cytoplasm, so 
myofibrillar proteins would have to be degraded inside lysosomes if the lysosomal system 
were involved. Lysosomes could not engulf a myofibril without destroying it, so the 
lysosomal system is not involved to a significant extent in metabolic turnover of 
myofibrillar proteins. The caspases are not activated until initiation of apoptosis, and, 






protein turnover. It seems that both the calpains and the proteasome are responsible for 
myofibrillar protein turnover, but the mechanism is still unknown. The proteasome is 
responsible for over 80 to 90% of total intracellular protein turnover, but the proteasome 
degrades peptide chains only after they have been unfolded, so that they can enter the 
catalytic chamber of the proteasome. Thus, although the proteasome can degrade 
sarcoplasmic proteins, it cannot degrade myofibrillar proteins until they have been 
removed from the myofibril. It remains unclear how this removal is done. Calpains 
degrade those proteins that are involved in keeping the myofibrillar proteins assembled in 
myofibrils, and calpains can disassemble the outer layer of proteins from the myofibril and 
releasing them as myofilaments. Such myofilaments have been found in skeletal muscle 
(van der Westhuyzen et al., 1981, Goll et al., 2003). Individual myofibrillar proteins can 
also exchange with their counterparts in the cytoplasm (Peng & Fischman 1991, Swartz 
1999), however, it is unclear whether this can be done to an extent that is consistent with 
the rate of myofibrillar protein turnover in living muscle. 
The proteasome has a major role in intracellular protein degradation in all cells. The 
ubiquitin proteasome system involves specific ubiquitin ligases (designated E3) attaching 
poly-ubiquitin tails on targets for degradation by the 26S proteasome. For example, both 
MuRF1 and MuRF3 have shown to specifically ubiquitinate and degrade myosin in a 
proteasome-dependent manner in the heart and skeletal muscle (Fielitz et al., 2007). 
MuRF1 is reported to also interact with troponin T, myosin light chain-2, myotilin, and 
telethonin (Witt et al., 2005). The closely related MuRF2 protein also interacts with these 
aforementioned proteins in vitro, suggesting that a redundant system may exist for turning 
over these proteins. In addition, MuRF1, found mainly in the M-line of the sarcomere 
where it interacts with the giant protein titin, specifically recognizes and degrades troponin 
I in a proteasome-dependent manner. Muscle atrophy F-box/Atrogin-1, C-terminus of 
Hsp70-interacting protein, and Murine double minute 2 are additional muscle-specific 
ubiquitin ligases having a role in maintaining the sarcomere (Willis et al., 2009). 
Calpains are required to mediate the dissociation of sarcomere proteins from the 
assembled myofibrillar structure before the ubiquitin-proteasome system (UPS) is able to 
degrade the sarcomere proteins (Neti et al., 2009). Calpains perform the initial proteolytic 
cleavage that allows E3 ubiquitin ligases to ubiquitinate the peptides and target them for 
degradation in the proteasome. Calpains do not degrade proteins to amino acids or even to 
small peptides and do not catalyze bulk degradation of the sarcoplasmic proteins, so they 
cannot be the only proteolytic system involved in myofibrillar protein turnover. No 
specific amino acid sequence is uniquely recognized by calpains. Amongst protein 
substrates tertiary structure elements rather than primary amino acid sequences are likely 
responsible for directing cleavage to a specific substrate.  
Calpains are a group of calcium-dependent, non-lysosomal cysteine proteases 
expressed ubiquitously in all cells. There are more than a dozen calpain isoforms some 
with multiple splice variants. The two main isoforms, calpain 1 and 2 differ primarily in 
their calcium requirements (Goll 2003). Calpain 3 (or p94) is a more tissue specific 
protease expressed in muscle and brain (Beckmann & Spencer 2008, Konig et al., 2003). 
Disruption of the gene encoding calpain 3 has been shown to cause muscular dystrophy. 






general degradative role in skeletal muscle, but it acts rather as a signaling protease. 
Calpains are able to cleave many cytoskeletal proteins and can thus intervene in 
cytoskeleton regulation, particularly during processes such as adaptive response to 
exercise or regeneration after muscle wasting (Ojima et al., 2010).  
A number of cytoskeletal proteins have been identified as potential calpain substrates 
in vitro, although not all have been confirmed as in vivo targets. These include 
myofibrillar/Z-disk proteins titin, α-fodrin, α-actinin, desmin, nebulin, filamin C, and 
myosin light chain 1, which supports the idea of calpain’s role in sarcomeric remodeling 
(Barta et al., 2005, Beckmann & Spencer 2008, Murphy, 2010).  
There is evidence that dysregulated protein turnover may play an important role in 
muscle or heart disease. When the calpain system is inhibited in the heart, as in mice over-
expressing the endogenous calpain inhibitor calpastatin, morphological evidence of 
widespread protein aggregation has been identified along with increased autophagy 
(Galvez et al., 2007). The coordinated effort by calpain and ubiquitin ligases is also 
illustrated in models of skeletal muscle atrophy. Ubiquitin ligases, including MuRF1, have 
proven to be essential in the atropic process. When calpain inhibitors are introduced into 
the system, sarcomere degradation is inhibited, thereby inhibiting muscular atrophy, 
without reducing the ubiquitin ligase levels (Fareed et al., 2006). 
3. Myopathies and muscular dystrophies 
A myopathy is a muscular disease in which the muscle fibers are dysfunctional, resulting 
in muscular weakness. Muscle cramps, stiffness, and spasm can also be associated with 
myopathy. 
A subgroup of myopathies, muscular dystrophies (MD), is inherited primary diseases 
of muscle, characterized pathologically by muscle fiber degeneration and clinically by 
muscle weakness. Classification of MD traditionally has been based on clinical, 
pathologic, and inheritance patterns (recessive, dominant, X-linked), but today gene 
mutation data have begun to dominate differential diagnostic methods (Rocha et al., 
2010). 
Nine diseases including Duchenne, Becker, limb-girdle, congenital, 
facioscapuohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss are always 
classified as muscular dystrophy but there are more than 100 diseases in total with 
similarities to muscular dystrophy (Kaplan et al., 2009, http://www.musclegenetable.org/). 
Most types of MD are multi-system disorders with manifestations in body systems 
including the heart, gastrointestinal and nervous systems, endocrine glands, skin, eyes, and 
brain. The condition may also lead to mood swings and learning difficulties.  
The most common and severe form of the disease, Duchenne muscular dystrophy 
(DMD), is a severe recessive X-linked form of muscular dystrophy characterized by rapid 
progression of muscle degeneration, typically leading to walking disability by the age of 
12 and eventually to death because of respiratory or heart failure. In general, only males 
are affected, though females can be carriers. The disorder is caused by a mutation in the 






tissue, providing structural stability to the dystroglycan complex (DGC) at the cell 
membrane. Mutations in the dystrophin gene can also cause a milder disease, Becker's 
muscular dystrophy (BMD), in which some patients can walk throughout their lives. The 
majority of DMD mutations cause the synthesis of a truncated, non-functional protein 
leading to loss of the whole DGC from the sarcolemma, resulting in instability of the 
muscle cell membrane, whereas mutations in the milder BMD leads to the production of a 
partially functional protein (Muntoni et al., 2003). 
3.1. Limb-girdle muscular dystrophy 
Limb-girdle muscular dystrophy (LGMD) is an autosomal class of muscular dystrophy 
that is similar but distinct from DMD and BDM. LGMD encompasses a large number of 
rare disorders with a significant genetic and clinical heterogeneity. The term limb-girdle 
describes the muscles most severely affected, the limb girdle muscles hips and shoulders. 
Common symptoms of limb-girdle muscular dystrophy are muscle weakness, 
myoglobinuria, pain, myotonia, cardiomyopathy, elevated serum creatine kinase, and 
rippling muscles. The muscle weakness is generally symmetric, proximal, and slowly 
progressive (Laval & Bushby 2004). 
The age of onset can be from early childhood to late adulthood and both genders are 
affected equally. When limb-girdle muscular dystrophy begins in childhood the 
progression appears to be faster and the disease more disabling than when the disorder 
begins in adolescence or adulthood (Laval & Bushby 2004).  
The discovery of genetically distinct subtypes of LGMD has led to its current 
classification based on inheritance patterns, with the autosomal dominant form designated 
as LGMD1 and the most common forms of LGMD, the autosomal recessive LGMDs 
named LGMD2. The classical grouping of the LGMDs into LGMD1 and LGMD2 is being 
complemented by a classification based on the involved proteins and the underlying 
genetic defects. Autosomal dominant LGMDs comprise seven forms, often found in only 
a few families. Typically, mutations lead to the expression of dominant-negative forms of 
the involved proteins. LGMD1A-C are genes for known proteins, myotilin (LGMD1A), 
lamins A/C (LGMD1B), and caveolin-3 (LGMD1C) (http://www.musclegenetable.org/). 
Myotilin and myotilinopathy are discussed in separate sections (2.3.1 and 3.3). Lamins 
A/C are involved in various neuromuscular, cardiac, and lipodegenerative diseases 
(Mounkes et al., 2001) and mutations in lamins A/C are predicted to perturb the structure 
of the nuclear envelope (Brodsky et al., 2000). LGMD1B is the most common and 
clinically most variable form of LGMD1s (Rocha et al., 2010). Caveolin-3 is the muscle-
specific member of the caveolin family of membrane proteins. Caveolins oligomerise in 
certain areas of the cell membrane, and constitute the coating of small membrane 
invaginations called caveolae, involved in membrane trafficking and cell signaling (Laval 
et al., 2004). Caveolin-3 is localized to the sarcolemma where it binds β-dystroglycan and 
dysferlin. Mutant caveolin-3 protein acts as a dominant negative inhibitor, oligomerizing 
with wild-type caveolin-3 and directing these complexes to proteasomal degradation 






G, have been described, but the causing genes have not been identified (Kaplan et al., 
2009, http://www.musclegenetable.org/). In general, dominant forms tend to present after 
the second decade of life. Except for a few cases with rapid progression, the course 
usually is slowly progressive. 
Compared with the dominantly inherited LGMD1 group, most autosomal recessive 
LGMDs have an earlier onset, rapid progression, and relatively high creatine kinase 
values. There are 15 currently known LGMD2s. LGMD2A, or calpain 3 deficiency, is the 
most common form of recessive LGMD (Rocha et al., 2010). Calpain 3 localizes to the 
skeletal muscle myofibrils by binding to titin (Beckmann et al., 2008, König et al., 2003). 
Titin has been proposed as a possible stabilizing agent that would prevent calpain 3 
degradation in muscle tissues (Sorimachi et al., 1993). Calpain 3 differs from the 
ubiquitous calpains 1 and 2 by several specific regions that confer its unique functions and 
by a monomeric structure. Calpain 3 differs also from most of the remaining calpains by 
working at physiological, submicromolar calcium concentrations, by turning over rapidly, 
and by a proteolytic activity that is not inhibited by the ubiquitously expressed calpastatin 
(Beckmann et al., 2008).  
There are no particular mutational calpain hot spots. The most common mechanism of 
LGMD2A is a deficiency in calpain 3 proteolytic activity, although there is a great 
heterogeneity in the LGMD2A associated calpain 3 mutations. The disease manifests in 
complete lack of calpain 3 expression, mislocalization of the protein, loss of enzymatic 
activity, or impairment of substrate cleavage or calpain 3 may simply perform other as yet 
unidentified non-proteolytic roles. Stretch-dependent calpain 3 distribution in sarcomeres 
plays a crucial role in the pathogenesis of LGMD2A, demonstrated with mice having 
endogenous calpain 3 replaced with a proteolytically inactive but structurally intact mutant 
protein (Ojima et al., 2010). There seem to be a correlation between type of mutation and 
phenotype (Kramerova et al., 2007, Beckmann et al., 2008).  
LGMD2B is caused by mutations in the dysferlin gene (DYSF), coding for a protein 
involved in membrane repair (Bashir et al., 1998). LGMD2C-F are all the result of 
mutations in one of the four sarcoglycans (α, β, γ, δ) (Ozawa et al., 2005). 
Sarcoglycanopathies mimic dystrophinopathies (DMD and BMD). The sarcoglycan 
complex stabilizes the association of dystrophin with dystroglycan and the extracellular 
matrix. The integrity of this complex contributes to the stability of the plasma membrane 
cytoskeleton (Thompson et al., 2000).  
LGMD2G is caused by mutations in the gene coding for telethonin, also called T-Cap. 
Telethonin is a titin capping protein at the myofibrillar Z-disk of the mature sarcomere, 
where it binds to FATZ-1, MLP and other proteins. During myofibrillogenesis, telethonin 
co-localizes with the M-band region of titin and is phosphorylated by the titin kinase 
domain (Frank et al., 2006). The disorder is relatively mild and has been reported in only 
five families to date. 
LGMD2H is caused by mutations in the TRIM32 gene, which encodes for a protein 
involved in the ubiquitin-proteasome degradation pathway. Tripartite motif-containing 32 
(Trim32) is an E3-ubiquitin ligase with anti-apoptotic properties and its over expression is 
associated to cancer development. Trim32 ubiquitinates α-actin in vitro, suggesting it’s 






LGMD2I is a common form of LGMD in northern Europe. The disease is the result of 
mutations of fukutin-related protein (FKRP), a glycosyltransferase involved in the O-
linked glycosylation of α-dystroglycan (Brockington et al., 2001). Mutations in FKRP lead 
to a marked reduction of α-dystroglycan at the sarcolemma (Brown et al., 2004). LGMD2I 
forms together with LGMD2K and LGMDM-O a group of disorders called 
dystroglycanopathies. LGMD2K is caused by mutations in the POMT1 gene, LGMD2M 
by mutations in the fukutin-encoding gene. LGMD2N is associated with mutations in the 
POMT2 and LGMD2O with the POMGNT1 protein (Kaplan et al., 2009, 
http://www.musclegenetable.org/). 
Titin is a sarcomeric protein connecting the Z-disk with the M-line and is associated 
with striated muscle development, structure, function and cell signaling. Tibial muscular 
dystrophy (TMD), a mild late-onset distal myopathy, results from heterozygous mutations 
of the titin (TTN) gene, whereas homozygosity for the same TTN mutation causes an 
autosomal recessive form of limb girdle muscular dystrophy  (LGMD2J), with early onset 
and a more severe phenotype (Hackman et al., 2002). 
LGMD2L has been linked to Anoctamin 5, also called TMEM16E or GDD1, is highly 
expressed in cardiac and skeletal muscle and in bone. The human Anoctamins compose a 
family of at least ten proteins of which some have been recognized as calcium-activated 
chloride channels, however, the function of Anoctamin 5 is unknown (Bolduc et al., 
2010). The putative calcium-activated chloride channel function of Anoctamin 5 may be 
connected to deficient skeletal muscle membrane repair in muscular dystrophies. 
Despite much progress over the last few years, the genetic cause of many cases of 
LGMD remains obscure and the classification of LGMDs is an ongoing process. Among 
the genetic causes of the autosomal dominant LGMDs, pure limb–girdle weakness appears 
to be a rather rare phenotype, whereas there is increasing awareness of presentations with 
distal myopathy or myofibrillar myopathy. The current treatment for LGMDs is 
supportive and aims at preventing complications, but gene therapy methods (exon 
skipping, stop codon read-through) are underway (Rocha et al., 2010). The major 
advances over the last two decades have improved diagnostic precision and focused 
symptomatic management and are increasingly leading to development of cutting-edge 
therapies. 
3.2. Myofibrillar myopathy 
Myofibrillar myopathies (MFMs) are morphologically distinct but genetically 
heterogeneous muscular dystrophies in which disintegration of Z-disks and subsequently 
myofibrils are followed by ectopic accumulation of multiple proteins as well as 
accumulation of degraded myofibrillar proteins forming large aggregates. MFM is 
characterized by slowly progressive weakness that can involve both proximal and distal 
muscles. Cardiomyopathy, neuropathy, and dominant inheritance are frequent associated 









Table 1. Limb-girdle muscular dystrophies and Myofibrillar myopathies 
(http://www.musclegenetable.org/, Mologni, 2009, Selcen, 2010) 
NAME HEREDITY GENE 
PRODUCT 
/LOCUS 
LOCALIZATION   
LGMD1A AD myotilin  sarcomere 
LGMD1B AD lamin A/C nuclear membrane 
LGMD1C AD caveolin-3 sarcolemma 
LGMD1D AD 6q23  
LGMD1E AD 7q  
LGMD1F AD 7q32  
LGMD1G AD 4p21  
LGMD2A AR calpain 3 sarcoplasm/sarcomere 
LGMD2B AR dysferlin sarcolemma 
LGMD2C AR γ-sarcoglycan sarcolemma 
LGMD2D AR α-sarcoglycan sarcolemma 
LGMD2E AR β-sarcolgycan sarcolemma 
LGMD2F AR δ-sarcoglycan sarcolemma 
LGMD2G AR telethonin sarcomere 
LGMD2H AR TRIM32  sarcoplasm/sarcomere 
LGMD2I  AR fukutin-related                   
protein 
sarcoplasmic reticulum 
LGMD2J AR titin sarcomere 
LGMD2K AR POMT1 sarcoplasmic reticulum 
LGMD2L AR Anoctamin 5 sarcolemma 
LGMD2M AR fukutin  golgi 
LGMD2N AR POMT2 sarcoplasmic reticulum 
LGMD2O AR POMGnT1 sarcoplasmic reticulum 
MFM AD desmin  sarcomere 
MFM AD α-B crystallin sarcoplasm/sarcomere 
MFM AD myotilin  sarcomere 
MFM AD ZASP (LDB3)  sarcomere 
MFM AD filamin C sarcomere 
MFM AD Bag3 sarcomere 
 
LGMD, Limb-girdle muscular dystrophy; MFM, Myofibrillar myopathy; AD, autosomal 









Myofibrillar myopathy has also been referred to as desmin storage myopathy, desmin-
related myopathy, or protein surplus myopathy. Because myofibrillar myopathy is 
genetically heterogeneous and the disease-causing protein or gene is known only in a 
minority of cases, because multiple other proteins besides desmin are also overexpressed 
in muscle, and because myotilin is not related to desmin, the noncommittal term 
“myofibrillar myopathy” is the preferred designation until the causative gene is 
determined. When the disease-associated gene/protein is identified, designations such as 
desminopathy, α-B crystallinopathy, myotilinopathy, zaspopathy, filaminopathy, or 
Bag3opathy are appropriate. 
The genetic basis of myofibrillar myopathy has been elucidated in only about 20% of 
cases. Mutations have been identified in DES, the gene encoding desmin; CRYAB, 
encoding alpha crystallin B chain; MYOT, encoding myotilin; LDB3 (ZASP), encoding 
LIM domain-binding protein 3; FLNC, encoding filamin C, and BAG3, encoding Bag3 
(Selcen, 2010). These proteins are all associated with the sarcomeric Z-disk and have 
common mechanisms that lead to similar morphologic features of these protein 
aggregates.  
3.3. Myotilinopathy 
Myotilin is mutated in various forms of muscular dystrophy: LGMD1A, MFM, distal 
myopathy, and spheroid body myopathy (SBM). The first myotilin mutation was revealed 
at the same time as its genetic locus was identified and caused LGMD2 in two families 
through a T57I substitution in the N-terminal serine-rich region of the protein. This T57I 
mutation does not affect the expression level or localization of myotilin within the 
sarcomere, nor the interaction with α-actinin (Hauser et al., 2000). LGMD1A has later 
been described in other rare families with proximal muscular dystrophy combined with 
dysarthria and modestly raised serum CK (Hauser et al., 2002). Affected muscles show 
disorganization and streaming of the Z-line. As the diagnostic spectrum of myotilin 
mutations has been better defined, it is now clear that an “LGMD” presentation is 
probably a rare form of myotilinopathy (its more common presentation is with a distal 
myopathy). Presentation tends to be in middle to late adult life. This form of LGMD 
therefore overlaps with the MFMs, where the affected muscles may be distal, proximal or 
a mixture, with typically moderately raised serum CK (approximately five times the upper 
limit of normal) and characteristic histological features including vacuoles and 
accumulation of myofibrillar proteins such as desmin and myotilin. MFM patients may 
also have related cardiomyopathy and peripheral neuropathy, fitting well with adult 
expression of the myotilin gene. In addition to the T57I mutation, the mutations S55F, 
S60C, S60F, and S95I in the serine-rich region of myotilin were identified as the cause of 
LGMD1A or MFM (Selcen et al., 2004). These substitutions change a polar, potentially 
phosphoryable serine or threonine to a hydrophobic residue. Later, families with myotilin 
mutations (K36E, Q47K, and S60F) were found with both proximal and distal myopathy 
(Olive et al., 2005, Penisson-Besnier et al., 2006) or mostly distal myopathy (S55F, S60F) 






myotilinopathies. To date, only one myotilin mutation has been found outside the serine-
rich region in one patient. The R405K mutation in the second Ig domain was shown to 
affects the homodimerization and α-actinin binding in yeast two-hybrid (Shalaby et al., 
2009). 
SBM has been described in only one family having the S39F mutation. The SBM 
patients have late-onset symptoms similar to LGMD1A, however, there is a unique pattern 
of spheroid bodies within the cytoplasm of type I fibers resembling the amorphous 
deposits observed in MFM patients (Foroud et al., 2005). 
Although the exact mechanism of how the myotilinopathy mutations lead to a disease 
phenotype is unclear, the mutations seem to have a dominant negative effect on the protein 
function. The finding that forced expression of myotilin in early times of muscle cell 
development prevents normal assembly of the sarcomeres (Salmikangas et al., 2003) 
supports this hypothesis. Furthermore, while myotilin knockout mice lack an obvious 
phenotype and seem to have normal muscle function (Moza et al., 2007), a transgenic 
mouse strain expressing the mutated T57I human form of myotilin unites the disease 
phenotype (Garvey et al., 2006). The T57I mice develop myofibrillar pathology 
progressing with age, including Z-disk streaming, myofibrillar vacuolization and 
myofibrillar aggregation. Protein aggregates include transgenic myotilin, endogenous α-








Aims of the study 
The aim of this study was to clarify the biological functions of myotilin and the molecular 
basis and the pathogenetic mechanisms that underlie myotilin-related diseases. Despite 
growing information on myotilin’s properties, its role in muscle function and disease is 
still poorly understood. The specific aims were: 
 
1) To study how myotilin regulates the actin cytoskeleton. 
 
 
2) To determine myotilin’s binding to Enigma proteins through a class III PDZ binding 
motif together with other myotilin and FATZ family proteins.  
 
 






Materials and methods 
Plasmids and Antibodies (I, II, III) 
Full-length myotilin-encoding gene (residues 1-498) and its variants encoding amino acids 
1-270 102-498, 185-498, 215-498, 347-498, 441-498, 217-250, 217-339, 217-439, 251-
439, 347-439, 347-498 or palladin (residues 715-772) were PCR-amplified from human 
myotilin or palladin cDNA and subcloned into pGEX-4T1 GST-fusion vector (Pharmacia) 
for production of GST fusion proteins in bacterial cells and into pAHP vector 
(Salmikangas et al. 2003), pDEST27 (Invitrogen), pEGFP-C2 (Clontech) for mammalian 
expression or in vitro translation, and into EG202 and JG4-5 vectors (Gyuris et al., 1993) 
for yeast two-hybrid analyzes. The PDZ domain regions of human ZASP (1-255 bp), ALP 
(1-246 bp) and CLP-36 (1-255 bp) were PCR-amplified from their respective full length 
cDNAs; subcloned into pQE30 (QIAGEN) and a modified version of pGEX-6-P3 (GE 
Healthcare) for the expression of His and GST-tagged proteins, respectively. The full-
length proteins of FATZ-1 and FATZ-2 were cloned as previously described (Faulkner et 
al., 2000). FATZ-3 (1-756 bp) was amplified by RT-PCR from human muscle mRNA 
(Clontech) and then cloned into pQE30 and the modified pGEX-6-P3. The site-directed 
mutations were generated by QuickChange Site-Directed Mutagenesis kit (Stratagene) 
according to the manufacturer’s instructions. The authenticity of the constructs was 
verified by sequencing the relevant regions. 
Myotilin was detected with a polyclonal rabbit antibody against myotilin residues 1-
151 or 231-342 (Mologni et al., 2005), ZASP with a polyclonal rat antibody (Faulkner, 
unpublished), α-actinin-2 (Sigma) with a monoclonal mouse antibody (m Ab), ezrin with 
the m Ab 3C12 (Sigma Aldrich), and ubiquitin with a m Ab (Santa Cruz Biotechnology). 
Mouse anti-HA Ab was used to recognize the HA-tag (Roche or Nordic Biosite AB) and 
goat anti-GST Ab (GE Healthcare) for the GST-tag. Alexa 488-, 568-, and 594-conjugated 
goat anti-mouse and goat anti-rabbit Ab:s (Invitrogen; MolecularPprobes) were used as 
secondary antibodies and F-actin was visualized with Alexa Fluor 568 phalloidin 
(Invitrogen, Molecular probes) in immunofluorescence. Coverslips were mounted in 
DABCO (Sigma) and Mowiol (Calbiochem) and examined by immunofluorescence 
(ZEISS Axiophot equipped with AxioCam cooled CCD-camera) and confocal microscopy 
(Leica SP2 equipped with Ar and Kr lasers, Leica microsystems). 
Cell transfections, treatments, and quantifications (I, II, III) 
Rat cardiomyocytes were isolated using the neonatal cardiomyocyte isolation system 
(Worthington Biochemical Corporation) according to manufacturer’s instructions, except 
that the tituration step was done twice. Cells were cultured in transfection medium (21% 
medium M199, 73% DBSS-K, 4% horse serum, 2 % L-glutamine; DBSS-K: 6.8 g/l NaCl, 






for 2 h and transfected with Escort III (Sigma) according to the manufacturer's protocol. 
Then 6 h after transfection, the media was changed to maintenance medium (75 % 
DMEM, 19 % M199, 4 % horse serum, 2 % L-glutamine, 50 µg/ml gentamycin 
(Invitrogen), 0.1 mM Phenyl Ephrine (Sigma), 10 µM AraC (Sigma)). Mouse muscle 
cryosections were prepared as described (Moza et al., 2007). COS7 and CHO-cells 
(ATCC) and male rat kangaroo kidney epithelial cells (PtK2 Line: ATCC) were 
transfected with Fu-GENE6 reagent (Roche) and incubated 48 h before analyzis. C2C12-
myofibroblasts (ATCC) were induced to differentiate into myotubes by shifting to culture 
medium containing 2% horse serum for 7-9 days. 
Calpain activity was induced with the addition of 5 µM ionomycin (Calbiochem, 
Merck KGaA) and 10 mM CaCl2 for 1 h and calpain was inhibited with 10 µM Z-Leu-
Leu-H (Z-LLal: PeptaNova GmbH) for 2 hrs. Protein synthesis was inhibited with 100 
µg/ml cycloheximide (Sigma), proteolysis with 10 µM Z-Leu-Leu-Leu-al (MG 132: 
Sigma-Aldrich Chemie GmbH), proteasomal degradation with 7.5 µM lactacystine 
(Calbiochem), lysosomal degradation with 10 µM Bafylomycin A (Sigma-Aldrich), and 
cysteine proteases with 20 µM E64D (Sigma). Actin filaments were destabilized with 0.5 
µM Latrunculin B (Sigma-Aldrich) for 7, 17, or 24 h. Cells were fixed, stained, and 
mounted as described (I, II). 
The morphology of the phalloidin stained actin cytoskeleton was analyzed from 100 
myotilin-transfected cells with different treatments and the experiment was repeated three 
times with similar results. The intensity of the Western blots were quantified by 
TyphoonImager 9400 (GE Healthcare) and analyzed by ImageQuantTL2003 software (GE 
Healthcare). Statistical analyzes were performed in Excel with Student´s t-test. 
Transposon and generation of a pool of 15 bp insertion-
containing mutant plasmids (I) 
Plasmid pJGMyo was used as a target for pentapeptide insertion mutagenesis. pJG4-
5(ΔNotI) was constructed by digestion of pJG4-5 with NotI and recirculation of the 
plasmid  after filling-in  with Klenow enzyme and dNTPs, eliminating a unique NotI site. 
The myotilin encoding region was also cloned into pJG4-5(ΔNotI) and this plasmid was 
used as a wt control for the created pentapeptide insertion mutants. The plasmid pSTH11, 
carrying the cat-Mu(NotI) mini-Mu transposon, has been described (Haapa et al., 1999). 
The linear cat-Mu(NotI) transposon was produced and purified as described (Haapa et al., 
1999). 
The in vitro transposition-based mutagenisation strategy exploits efficient Mu in vitro 
transposition reaction (Lamberg et al., 2002) in combination with custom-designed cat-Mu 
(NotI) mini-Mu transposon (Haapa et al., 1999). Standard in vitro transposition reaction 
(25 µl) contained 180 ng cat-Mu (NotI) transposon DNA as the donor, 850 ng plasmid 
pJGMyo as a target, 0.2 µg MuA, 25 mM Tris-HCl pH 8.0, 100 µg/ml BSA, 15% w/v 
glycerol, 0.05% w/v Triton X-100, 126 mM NaCl, and 10 mM MgCl2. Six individual 
standard reactions were pooled, DNA extracted and resuspended in 20 µl water. Individual 






DH5α cells (Life Technologies). Transposon-containing plasmid clones were selected by 
ampicillin (Amp) and chloramphenicol (Cm) resistance. A total of ~1x105 colonies were 
pooled and grown in LB-Amp -Cm liquid medium (50 ml) at 37 °C for 2 h. Plasmid DNA 
from the pool was isolated, digested with EcoRI and XhoI and subjected to preparative 
electrophoresis on 0.6% agarose gel. The 3.2 kb DNA fragment pool, corresponding to 
transposon insertions into the myotilin-encoding DNA segment, was isolated and ligated 
into EcoRI-XhoI-digested plasmid pJG4-5 (ΔNotI). The ligation mixture was 
electrotransformed as above into MC1061 cells (Invitrogen), and plasmid DNA was 
prepared from ~3x104 colonies as described above. Most of the transposon sequence was 
then excised by cleavage with NotI followed by preparative electrophoresis and isolation 
of the plasmid backbone as above and recircularisation by ligation at low DNA 
concentration (~0.1 ng/µl). Ligated plasmids were electroporated into DH5α cells and 
selected on LB-Amp plates. The final insertion mutant plasmid library contained  ~3x104 
clones.  
Insertion positions were determined roughly by initial restriction analysis with EcoRI-
NotI and NotI-Xho. Interesting phenotype-generating mutation constructs were sequenced 
with vector-specific 5' and 3' primers and with a myotilin primer corresponding to amino 
the acids 214 - 220 in the protein. The sequenced plasmids were individually transformed 
into S. cerevisiae cells for morphological analysis. 
Protein purification (I, II, III) 
The pGEX expression plasmids containing cDNAs for α-actinin2, myotilin, pallladin, 
FATZ-1, -2 and -3 with and without the last 15 bp were transformed into E. coli BL21 
(pLysS) cells. The pQE expression plasmids containing the cDNAs for the PDZ region of 
ZASP, ALP and CLP-36 were transformed into E. coli M15 cells. Protein expression was 
induced with 0.3-1.0 mM IPTG (isopropyl-β-D-thiogalactopyranoside) for 3-4 h at RT, 
and GST- and His-tagged proteins were purified respectively with glutathione-Sepharose 
beads (GE Healthcare) and Ni-NTA resin (QIAGEN) according to the manufacturer’s 
protocol for native protein. 
For the actin bundling assay, each myotilin fragment was released from the GST 
fusion by incubation for 1 h at RT with 10 U of thrombin (Sigma) in cleaving buffer (150 
mM NaCl, 2.5 mM CaCl2 in 50 mM Tris, pH 8). Thrombin was removed from the 
samples by Benzamidine Sepharose 6B beads (Amersham Pharmacia Biotech). The 
fragment containing α-actinin repeats R1-R4 (lacking the actin-binding domain) was 
expressed and purified as described (Young et al., 1998). 
Actin-binding assay (I) 
Actin filaments were assembled from purified rabbit skeletal muscle actin in G-buffer (5 






10 x polymerizing mixture (500 mM KCl, 20 mM MgCl2, 10 mM ATP) and incubated at 
RT for 1 h. Purified myotilin (1.5 µM), α-actinin (1 µM) (Cytoskeleton, Inc.) and α-actinin 
R1-R4 (1 µM) was added to the actin filaments (3 µM). Reaction volumes were equalized 
to 50 µl with G-buffer. The mixture was incubated at 25°C for 30 min and subsequently 
centrifuged at 14,000 g for 3 min. Under these centrifugation conditions, actin filaments 
remain in the supernatant, whereas F-actin bundles sediment. The pellet and supernatant 
was separated and their volumes were equalized with Laemmli buffer. The samples were 
analysed for protein content by SDS-PAGE and Coomassie blue staining. The relative 
amount of actin, that was precipitated or remained in the supernatant, was evaluated by the 
NIH-image program from SDS-gels from at least three independent experiments. 
In vitro binding assay (II) 
For the in vitro binding assay pCMV-myc-FATZ-3 or pAHP-myotilin or palladin 
plasmids were used as templates in a T3 or a T7-coupled rabbit reticulocyte transcription-
translation system (Promega). Approximately 4 µg of GST-fusion proteins on glutathione 
beads were incubated with 15 µl of in vitro translated, 35S-labelled protein in 10 mM Tris-
HCl, pH 7.5, 5 mM EDTA, 130 mM KCl, 0.05 % Tween-20. After washes with the same 
buffer, bound material was eluted by boiling in Laemmli buffer, subjected to SDS-PAGE 
and detected by autoradiography. 
Yeast two-hybrid analysis and morphological observations of 
yeast phenotype (I) 
Yeast transformation and mating as well as detection of protein interactions by β-
galactosidase activity were previously described (Grönholm et al., 1999; Rönty et al.; 
2007). The growth rate of myotilin expressing yeast-cells was measured or baits and preys 
were mated and replica tested for β-galactosidase activity to indicate the interaction 
between actin and the different myotilin constructs. The level of myotilin expression was 
verified by immunoblotting. Alternatively, the C-terminal myotilin cDNA, encoding for 
amino acids 102-498, was introduced by PCR and conventional cloning to a yeast two-
hybrid bait plasmid pGBKT7. The bait was used in screening of a human skeletal muscle 
library in pACT2 (Clontech). Positive clones were sequenced. 
To visualize F-actin and the cell wall, fixed cells were pelleted and incubated with 0.66 
µM rhodamine phalloidin (Molecular Probes) and 0.1 mg/ml calcofluor in PBS for 1 h. 
Cells were washed with PBS and suspended in DABCO (Sigma) mounting solution. The 
phenotype of different yeast clones was determined by DIC and immunofluoresence 








The program to extract proteins from any database with the last 5 amino acids having the 
motif E[ST][DE][DE]L was written by Prof. G. Valle, Genome Research Group, CRIBI, 
University of Padova. The last 8 amino acids were considered but only the terminal 5 
amino acids were given the following weightings: position 0 L = 2, position 1 E or D = 1, 
position 2 E or D = 1, position 3 S or T = 1 and position 4 E = 1. A score of 6 was given 
when all the criteria are met. This program was used to check the UniProt Knowledgebase 
Release 11.3 (UniProtKB/Swiss-Prot Release 53.3 of 10-Jul-2007 and the 
UniProtKB/TrEMBL Release 36.3 of 10-Jul-2007). 
Peptides and AlphaScreen (II) 
The peptides used for this study were synthesized by the ICGEB peptide synthesis service 
using a Gilson AspecXL SPE robot. The linker made up of two gamma amino-butyric acid 
units was 12.3 Å in length. The following peptides were used: Biotin-GABA-GABA-
EpSEEE, -ESEEE, -EpSEEL, -ESEEL, -EpTEEL, -ETEEL, -EpSEDL,-ESEDL, -
EpSEDL, -ESDEL and –EpSDEL. For competition experiments the same peptides without 
biotin but with GABA were used. 
Experiments were done using 384-well plates (OptiPlate-384 white opaque, Packard 
BioScience) in a final volume of 25 µl per well. Both the GST detection and the Histidine 
detection Kits for AlphaScreen were used according to the manufacturer’s specifications 
(Perkin Elmer). The acceptor and donor beads were used at a concentration of 0.02 µg/µl 
(6.5 pM). First the protein(s) to be tested are added to the wells and immediately the 
acceptor beads are added. The following steps were done in the dark; the plate was 
incubated for 30 min at RT before adding the donor beads; then for a further 3 hours after 
which it was kept for 15 min at 28˚C to equilibrate the temperature. The signal was read at 
28°C using a Fusion AlphaTMMultilabel Reader (PerkinElmerTM) at 300 ms excitation, 
700 ms emission. 
When testing a protein for binding it is necessary to titrate it against its partner to 
establish the concentration of both proteins resulting in a significant value for the ratio of 
the signal (S) to noise (N), normally S/N 8-50. In every experiment negative controls 
without one or both proteins were used to give the noise (background) level and 
biotinylated GST (0.5nM) or biotinylated His (1nM) were used to as internal controls to 
normalize the signal. The experiments were repeated at least 3 times. In the competition 
experiments the binding proteins were first added to the wells at a fixed concentration that 
would result in binding in the absence of a competitor and then the protein used as 
competitor was added at decreasing concentrations. The results were plotted as the ratio of 
the signal in the presence of the competitor divided by that of the signal in the absence of 
the competitor. These experiments were repeated at least three times, the mean and the 







The Ratio is calculated as the mean of the normalized Signal divided by the mean of the 
normalized Noise ie    
 





Sm = normalized signal mean;  dSm= mean standard deviation of normalized signal 
Nm = normalized noise mean;  dNm= mean standard deviation of normalized noise 
TranSignal PDZ Array Domains (II) 
The PDZ array membranes (Panomics) were used according to the protocols in the 
manufacturer’s handbook; the biotinylated peptides or His –tagged purified proteins were 
used as ligands at 0.3 µg/ml and 15 µg/ml, respectively. After chemiluminescence the 
membranes were exposed to Hyperfilm for ECL (GE Heathcare). 
Phosphorylation experiments (II) 
Four µg of GST fusion proteins were used for each reaction. For phosphorylation studies 
with rat skeletal muscle extract, soleus and gastrocnemius muscle specimens were 
prepared freshly from rats, cut into 1-2 mm piaces, frozen in liquid nitrogen for 2 h, and 
maintained in - 80°C until needed. The protocol used for the CaM Kinase II 
phosphorylation assays is that described by Upstate Biotechnology, the only difference 
being that samples were analyzed by SDS-PAGE instead of using a scintillation counter. 
The CaM Kinase II enzyme used was from Upstate Biotechnology (catalog no.14-217, 
active, CaM Kinase II purified from rat forebrain). The protocol for the PKA 
phosphorylation assays is that described by Alfthan et al., 2004. 
In vitro proteolysis with calpain 1 (III) 
75 mg rat skeletal muscle was pulverized in a chilled mortar with liquid nitrogen and 
homogenized by sonication in ice-cold reaction buffer in the absence of Ca2+. The crude 
homogenates were subsequently incubated as described previously (Barta et al. 2005). 
Calpain 1 proteolysis was initiated by the addition of 1 or 5 U calpain 1 (Calbiochem) to 






immediately boiled in Laemmli buffer. Mixtures incubated in the presence of protease 
inhibitors 10 µM Z-LLal, 75 µM E-64d, 500 µM calpeptin (Calbiochem), 1 mM PMSF 
(Merck), 3 µM aprotinin, 5 µg/ml pepstatin A, 2 µg/ml leupeptin (Sigma-Aldrich), or in 
the absence of Ca2+ served as controls. Alternatively, C2C12 cells differentiated for 7-9 
days were lysed in ice-cold reaction buffer and incubated in the presence of 2.5 U calpain 
1 with or without Z-llal or Ca2+ for 30 min in 30°C. Incubations in the absence of calpain 
1 were used to test the endogenous Ca2+–dependent proteolytic activity. 
GST-myotilin fragments were expressed in E. coli DH5α and purified as described 
previously (I). Glutathione-sepharose beads with 4 µg fusion protein were incubated with 
0.4 U of recombinant, active calpain 1 (Human erythrocytes: Calbiochem) in 30 µl calpain 
buffer (20 mM Tris-HCl, 30 µM CaCl2 pH 7.4) with or without 10 µM calpain inhibitor Z-
LLal for 5 min at RT. A mixture without calpain served as control. Adding 25 µl of 
Laemmli reducing buffer stopped the reaction. Proteins were resolved in SDS-PAGE, 
blotted, and detected with myotilin antibodies or with silver staining. Equivalent loading 
of the GST fusion proteins was confirmed by immunoblotting with goat anti-GST 
antibody. Fragments including GST and amino acids 217-250 or 217-339 of myotilin were 
alternatively analyzed by mass spectrometry. 
MALDI-TOF analyses (III) 
The calpain digestion reaction was made directly on MALDI target plate. Then, a 
saturated matrix solution α-cyano-4-hydroxy cinnamic acid (CHCA) (Sigma) in 33% 
ACN/0.1% TFA was added. MALDI-TOF analyses were carried out with Autoflex III 
(Bruker Daltonics) equipped with a SmartBeam™ laser (355 nm), operated in positive and 
reflective modes. Typically, mass spectra were acquired by accumulating spectra of 2000 
laser shots and up to 10 000 for MS/MS spectra. External calibration was performed for 
molecular assignments using a peptide calibration standard (Bruker Daltonics).  
Peptide identifications were performed by searching the peptide monoisotopic masses 
for Peptide Mass Fingerprints or the amino acid sequence tag for peptide fragments in 
MS/MS against NCBInr database using Matrix Science’s Mascot 
(http://www.matrixscience.com/, Matrix Science Ltd) / or against locally created databases 
in an intranet server. FlexAnalysis™ and Biotools™ softwares (Bruker Daltonics) were 
used to analyze MS data as search engine interface between raw data transfer and the 
databases in mascot server, respectively. The following parameters were set for the 
searches; 0.1 Da precursor tolerance and 0.5 Da MS/MS fragment tolerance for combined 







Results and discussion 
Myotilin binds both G- and F-actin in vitro (I) 
Myotilin localizes to structures that contain contractile bundles of actin filaments, such as 
stress fibers in transfected fibroblast cells and sarcomeres in muscle cells. Previous studies 
had shown that myotilin binds F-actin directly at a 1:1 ratio and cross-links actin filaments 
into large, stable bundles in vitro seen in electron microscopy. In cultured cells, expression 
of myotilin results in a unique phenotype with a network of filaments consisting of F-actin 
and myotilin. Furthermore, forced expression of myotilin in early times of muscle cell 
development leads to strong actin bundle formation, which prevents normal assembly of 
sarcomeres (Salmikangas et al., 2003). These actin-regulating properties of myotilin are 
rather unique, and these characteristics provided excellent possibilities to study actin 
regulation.  
This study characterized further the interaction between myotilin and actin. To provide 
molecular insight into the myotilin-actin interaction, a number of truncated and mutated 
myotilin variants were prepared and the function of these fragments was studied by 
several different assays. The effect of various myotilin domains on myofibrillogenesis has 
previously been reported (van der Ven et al., 2000, Salmikangas et al., 2003) and therefore 
these studies focused on cells not expressing endogenous myotilin. Myotilin bound both 
G- and F-actin in vitro, shown by a G-actin pull-down assay and by an F-actin co-
sedimentation assay. Binding efficiency correlated with construct size, that is, longer 
fragments bound actin better. By recruiting G-actin to the Z-disks, myotilin could be an 
important player during initial steps of sarcomeric remodeling in myofibrillar alterations 
induced by eccentric exercise. The amounts of myotilin and F-actin are strongly increased 
in broadened sarcomeres after eccentric exercise, where new sarcomeres are inserted, 
while there is a temporary lack of α-actinin (as well as titin and nebulin) (Carlsson et al., 
2006).  
During yeast two-hybrid experiments, we noticed that yeast cells expressing myotilin 
showed retarded growth. Microscopic analysis demonstrated phenotypic alterations in the 
same cells. This led us to further analyze the effect of myotilin on yeast actin cytoskeleton 
and to develop an assay for rapid screening of myotilin mutants with defective function. 
This assay combined in vitro DNA transposition-based peptide insertion mutagenesis with 
phenotype analysis in yeast cells. We found that myotilin induced exceptionally thick 
actin bundles that spanned throughout the chain of unseparated myotilin-expressing yeast 
cells. We are not aware of any other protein with such a strong actin-bundling effect in 
yeast. The phenotype resembled that seen in COS7 cells and, together with yeast two 
hybrid results, indicates that the binding and bundling properties of myotilin are conserved 
between mammalian and yeast actin. The fact that myotilin-induced changes were also 
seen in the actin phenotype mutant yeast strains, in which important actin-binding proteins 
(tropomyosin, Sac 6 [fimbrin], Abp1, Cap2, coronin, Aip [actin-interacting protein], 







Myotilin Ig-domains are important for interaction with actin (I) 
We wanted to identify the specific region of myotilin responsible for actin binding. 
Analysis of the sequence of myotilin did not reveal any of the canonical actin-binding 
domains described for other actin-modifying proteins (dos Remedios et al., 2003). The 
shortest fragment of myotilin to bind actin was the second Ig-domain together with a short 
C-terminal sequence. However, both Ig-domains proved to be of functional importance 
both for actin binding and bundling. Deletion of either Ig domain did not abolish, but 
weakened actin binding both in the pull-down and transfection experiments. These results 
suggest that the Ig domains may bind actin separately, but the combined effect of both 
domains is needed for optimal myotilin–actin interaction. The result is in line with 
functional studies of other Ig domain-containing muscle proteins, in which tandem Ig 
domains are required for proper function. For instance, the interaction between titin and 
telethonin has been shown to depend on Ig domains Z1Z2 of titin. Neither an extension of 
the N- nor C-terminus of separate Ig domains induced telethonin binding, suggesting that 
the binding region was not located at the linker region between the two Ig domains (Zou et 
al., 2003). Myotilin 185–498 was the shortest construct to induce actin-bundling activity 
in vitro and in vivo. This result indicates that the mere actin-binding region is not 
sufficient for the bundling effect. Deletion of either Ig1 or Ig2 hindered actin bundle 
formation in cells but did not inhibit the dimerization of myotilin, suggesting that myotilin 
bundles actin through two actin-binding sites. 
Through possible combinatorial interactions with additional actin and alpha-actinin 
binding proteins that localize to the Z-disk (filamin C, FATZ-1), myotilin is involved in 
actin stabilization and Z-disk function (Salmikangas et al., 2003, van der Ven et al., 2000, 
Gontier et al., 2005). Hence, myotilin mutations could interfere with the total actin-
tethering capacity of the Z-disc. Neither the region in myotilin that binds α-actinin (amino 
acids 80-125) (Hauser et al., 2000) nor the disease-associated substitutions in myotilin, all 
of which reside between residues 55 and 95, were, however, required for actin bundling. 
This result suggests that the pathogenetic mechanism of myotilin mutations is independent 
of its actin-modulating effects. 
Overall, our findings define the Ig-domain segment of myotilin as critical for the 
interaction with actin and indicate that the region of interaction is conserved between yeast 
and mammalian actins. Later, a kettin fragment containing only the four C-terminal Ig 
domains was shown to bind directly to F-actin (Ono et al., 2006), suggesting that binding 
of actin by Ig domains may be a highly conserved molecular mechanism shared by both 
vertebrate and invertebrate proteins. Recently also palladin, the closest homologue to 
myotilin, was shown to bind and bundle actin through two of its Ig-domains (Dixon et al., 
2008). Traditionally, Ig domains are known to mediate protein–protein interactions, serve 
as dimerization sites, or act as modular “spacers” to place an interacting module in the 
correct position to perform its function. Our study, together with some other observations, 
indicates that one should also regard the Ig domain as an actin-binding domain. However, 
the precise mechanism is still unknown and needs further investigation. Also the structural 
data on the actin-binding motifs in myotilin and palladin are under investigation. The 






(Heikkinen et al., 2009), however, more structural information is needed to define the 
specific structural features that identify an actin-binding type of Ig domain. 
ZASP is a new binding partner for myotilin (II) 
Interactions between Z-disk proteins regulate muscle functions and disruption of these 
interactions results in muscle disorders. Dominantly inherited missense mutations in Z-
disk components myotilin, myopalladin, ZASP (Cypher), and FATZ-2 can lead to disease 
of the skeletal muscle and/or the heart. To search for novel binding partners to myotilin, 
we screened a human striated muscle library with the yeast two-hybrid method using a C-
terminal fragment of myotilin as bait and identified ZASP as a new binding partner of 
myotilin. The interaction was verified with in vitro and in vivo (rat cardiomyocytes) 
affinity assays and cell transfection experiments. We further mapped the regions 
mediating this interaction to the extreme C-terminus of myotilin and the N-terminal PDZ 
domain of ZASP. PDZ domains typically bind to motifs located at the extreme C terminus 
(Sheng et al., 2001) and containing a crucial C-terminal leucine. The C-terminal residue of 
myotilin is a leucine and thus part of a potential PDZ binding motif. When the leucine in 
myotilin was replaced by glutamic acid, binding was lost both to the full-length 
ZASP/Cypher and the ZASP/Cypher PDZ domain. 
The myotilin and FATZ families share a conserved 
E[ST][DE][DE]L motif that mediates interaction with muscle-
specific PDZ domains (II) 
Together with our collaborators, we noted that the C-terminal 5 amino acids of myotilin 
share high similarity with palladin, myopalladin and the family of three FATZ 
(calsarcin/myozenin) proteins. This high similarity raised the question of whether all these 
proteins could interact via their C termini with the PDZ domain of ZASP or the PDZ 
domains of other proteins. We showed with bioinformatics that the C-terminal 
E[ST][DE][DE]L motif is present almost exclusively in the myotilin and FATZ protein 
families and is evolutionary conserved. Based on previous classification of PDZ-binding 
motifs (Hung & Sheng, 2002, Songyang et al., 1997), the C-terminal ligand motif of 
myotilin and FATZ family proteins characterized in this study can be considered as a 
novel type of class III PDZ binding motif. 
We used affinity precipitation assays, colocalization studies, the quantitative 
AlphaScreen technique, and a PDZ domain array to show that proteins from the myotilin 
and FATZ families interact via this novel type of PDZ binding motif with the PDZ 
domains of ZASP and other Enigma family members: ALP, CLP-36, and RIL. The PDZ 
domain array demonstrated that the interaction of the FATZ and myotilin families with the 
Enigma family members is highly specific, since the only two Enigma family members, of 






Consistent with previous results (Kim & Sheng 2004) we showed that the interactions 
between the PDZ domains and their ligands are modulated by phosphorylation. Except for 
the finding that Src phosphorylates palladin (Rönty et al., 2007), no information on the 
interplay between kinases and the myotilin or FATZ families was available. We showed 
that muscle lysate contains kinase activity that can phosphorylate myotilin and tested then 
whether kinases associated with muscle pathophysiology can phosphorylate the C-termini 
binding to Enigma family PDZ domains.  Calmodulin-dependent kinase II phosphorylated 
the C-terminus of FATZ-3 and myotilin, whereas PKA phosphorylated that of FATZ-1 
and FATZ-2.  
In muscle, PDZ proteins function as adaptors in translating mechanical stress signals 
from the Z-disk to the nucleus (Hoshijima, 2006). Some members of the Enigma family of 
PDZ proteins, ZASP for example, are known to bind protein kinases via their C-terminal 
LIM domains. Therefore, it is possible that ZASP and some other Enigma family proteins 
link the proteins of the myotilin and FATZ families to signaling events such as PKC 
phosphorylation.  In this study we demonstrated that several of the known disease-
associated Z-disk proteins are part of the same structural complex, whose composition can 
be regulated by signaling molecules associated with pathophysiological stimuli. 
This was the first report of a binding motif common to both the myotilin and the FATZ 
families that is specific for interactions with Enigma family members. Our results were 
confirmed by the studies from another group demonstrating the specific binding of ZASP 
PDZ domain to the C-terminal region of both FATZ-2 and myotilin within the Z-line 
(Zheng et al., 2009). Also the interaction between palladin and CLP-36 was later 
confirmed. The interaction was dependent on the PDZ domain of CLP-36 and the C-
terminus of palladin, and silencing of palladin inhibited the localization of CLP-36 to 
stress fibers (Maeda et al., 2009). Another group showed by yeast two-hybrid that the PDZ 
domain of CLP-36 and the last three amino acids (EDL) were needed for the protein 
interaction. Also mystique and RIL, two other members of the ALP/enigma protein 
family, bound to the C-terminus of palladin (Hasegawa et al., 2010). 
Myotilin is a substrate for calpain (III) 
The morphological findings typical of myofibrillar myopathy (MFM) include Z-disk 
alterations and aggregation of dense filamentous material (Clemen et al., 2009). The 
causes and mechanisms of protein aggregation in myotilinopathies and other MFM 
patients remain unknown; however, impaired protein degradation may explain in part the 
abnormal protein accumulation. In myotilinopathy patients, myotilin containing filament 
aggregates are immunostained for ubiquitin and the biologically dysfunctional mutant 
form UBB+1. Also the polyubiquitin-binding protein p62, a multimeric signal protein 
known to be involved in aggregate formation, is found in myotilin positive aggregates 
(Olivé et al., 2008).  
To gain more information about the degradation of myofibrillar proteins, we studied 
the mechanisms that control myotilin turnover. Calpains are required to mediate the 






ubiquitin-proteasome system is able to degrade them. Calpains perform the initial 
proteolytic cleavage that allows E3 ubiquitin ligases, MuRF1 for example, to ubiquitinate 
the peptides and target them for degradation in the proteasome. In this study, we reported 
that myotilin is a calpain substrate in vitro, in cells, and in muscle tissue. The interplay 
between myotilin and calpain is in line with their colocalization in the Z-band and under 
the plasma membrane in mouse skeletal muscle fibers (Raynaud et al., 2006).  
Our results indicated that the rat muscle myofibril has the potential to modulate its 
proteins, myotilin for example, via its own calpains. In mature sarcomeres, myotilin co-
localizes with α-actinin and Z-disk titin, showing the striated pattern typical of sarcomeric 
proteins. In skeletal muscle, calpain cleavage of myotilin could be required for 
reorganization of muscular fibres after eccentric exercise. Myotilin is present in increased 
amounts in lesions related to Z-disk streaming and events leading to insertion of new 
sarcomeres in pre-existing myofibrils induced by eccentric exercise (Carlsson et al. 2007). 
Myotilin is more associated to F-actin than to the core Z-disk protein α-actinin during 
these events and might dissociate from α-actinin by calpain cleavage. Goll et al. (1991) 
have suggested that calpain 1 may release α-actinin from the Z-line intact via the 
modulation of other interacting proteins. α-actinin has also been shown to be least 
susceptible to calpain 1 proteolysis of several myofibrillar proteins (Barta et al., 2005). 
Myotilin appears already during initial steps of the remodelling process, before α-actinin, 
titin and nebulin, to the new sarcomeres. The susceptibility to calpain 1 cleavage leading 
to further degradation and release of new building blocks, could explain the rapid turnover 
of myotilin when the level of calcium in muscle cells is high during muscle contraction. 
For example, in cultures of quail myotubes, myotilin has a fast recovery rate compared to 
six other Z-disk proteins by FRAP (Wang et al., 2005).  
We identified two calpain cleavage sites in myotilin, one at the amino terminal side of 
Q226 and the other at the amino terminal side of I253, by mass spectrometry. There are no 
consensus sequences for calpain cleavage, but they usually cleave destructured regions 
and both calpain cleavage sites in myotilin resided at a destructured region before the first 
Ig-domain.  
Degradation of myotilin by the proteasomal pathway (III) 
We showed with proteasome inhibitors that myotilin is further degraded by the 
proteasome in transfected COS7 cells and in C2C12 myotubes expressing myotilin. 
Treatment of myotilin expressing cells with proteasome inhibitors induced morphological 
changes where myotilin accumulated in aggregates or dots, which also contained F-actin. 
The dots concentrated around the membranes and the normal actin cytoskeleton was 
partially intact. This indicates that when the ubiquitin proteasome system is disturbed in 
cells, the turnover of myotilin is dysfunctional leading to protein accumulations containing 
myotilin and actin filaments. The turnover of myotilin in the myotubes with organized 
sarcomeres is slower than in the fibroblast cells. When the filamentous actin structures in 
the myotubes were disrupted with latrunculin B, the degradation of myotilin became 






from the myofibril before they can be degraded downstream to amino acids by the 
proteasome and cellular peptidases (Solomon & Goldberg, 1996). 
 
Figure 3. Schematic picture of events after calpain cleavage of myotilin in muscle cells. Calpain 
cleavage of myotilin at sites amino-terminal to the first Ig-domain (1) leads to myofibrillar 
reorganization (2a). Alternatively, myotilin turnover is initiated by calpain cleavage. The cleavage 
is not affected by disease-causing mutations. Cleaved myotilin undergoes degradation via the 
ubiquitin-proteasome system (2b) (and additional mechanisms). Mutated myotilin is more resistant 
to degradation. This leads to accumulation of myotilin and induction of actin-containing protein 






Mutant myotilin is more resistant to degradation than wild type 
protein (III) 
We demonstrated that proteins with myotilinopathy mutations degrade more slowly than 
wt myotilin. Previously, mutations in myotilin have been tested for their role in myotilin 
dimerization, interaction with α-actinin and actin, actin bundling, and myotilin 
phosphorylation, but the studies have not revealed differences with wild type myotilin. 
The results shown here, for the first time indicate a functional difference, as the patient 
mutations showed to be more resistant to degradation than the wt protein. We show that if 
the degradation of myotilin is disturbed, it accumulates in cells in a manner resembling 
that seen in myotilinopathy patients. This is supported by the fact that the amount of 
myotilin in the patient's muscle samples is increased (Barrachina et al., 2007, Shalaby et 
al., 2009). Based on the results, we propose a model on the pathogenic mechanism, by 
which myotilin mutations induce muscular dystrophy (Figure 3).  In this model, mutated 
myotilin is more resistant to proteolytic breakdown, which leads to accumulation of 
myotilin and induction of actin-containing protein aggregates. Protein aggregation is not 
only a secondary defect, since we showed that cells transfected with GFP myotilin (in 
opposite to GFP transfected cells) induced protein aggregates after proteasome inhibition. 
The aggregates may become toxic when sequestering essential cellular proteins and 
eventually cause myopathy by disrupting the myofibrils. In addition, mutant myotilin may 








In conclusion, this study gave new information about myotilin’s interaction with actin and 
identified new interaction partners, ZASP, CLP-36, ALP, and RIL. All, except RIL, are 
components of the muscle Z-disk. Our aim was to get more information about myotilin, 
which in our laboratory had been identified as an α-actinin binding protein in human 
striated muscle (Salmikangas et al., 1999). We developed various cell culture models, 
functional assays, recombinant proteins and synthetic peptides to aid in understanding 
how myotilin functions in muscle. In the beginning of our studies, a missense mutation 
T57I in myotilin was known to cause one form of skeletal muscle disease, LGMD1A 
(Hauser et al., 2000). Later, more mutations were found that substituted a serine or 
threonine for another amino acid in the protein causing different muscle diseases, now 
collectively termed myotilinopathy. The α-actinin-binding site in myotilin resides in the 
N-terminal region where the patient mutations were found. Therefore, we studied how 
deletion or mutation of this part in myotilin affects the actin-organizing properties of 
myotilin. We showed that neither α-actinin-binding nor actin bundling was affected by the 
mutations in myotilin. Another hypothesis was that myotilin would be phosphorylated at 
the serine-rich region and that the mutations would affect this phosphorylation. We, 
however, did not find any phosphorylation of myotilin in the serine-rich area.  
Except for the finding that Src phosphorylates palladin (Rönty et al., 2007), no 
information on the interplay between kinases and the myotilin or FATZ muscle protein 
families was available. In this study we showed that the interaction between myotilin and 
the Z-disk ptoteins ZASP and CLP-36 is regulated by phosphorylation. Many Z-disk 
proteins have been found since this study began. At that time the sarcomere was thought 
to be a static structural unit and myotilin was defined as a core structural protein. Now it is 
known that the nature of the Z-disk allows it to serve both as a structural unit and as a 
coordinator of intracellular signaling. The Z-disk can respond to external stimuli by 
dissolution and reorganization, which requires dynamic and coordinated dissociation and 
association of molecular interactions. Phosphorylation of myotilin as well as palladin and 
the FATZ family proteins, shown in this study, is one way of regulating the protein-
protein interactions in the sarcomere. In addition, it is possible that ZASP and some other 
PDZ-domain-containing proteins link the proteins of the myotilin and FATZ families to 
signaling events such as PKC phosphorylation. Based on the work presented here, we 
propose that the FATZ and myotilin families bind to members of the Enigma family of 
PDZ proteins (ZASP, CLP-36, ALP, and RIL) via the E[ST][DE][DE]L C-terminal ligand 
motif that can be considered a novel class III PDZ domain binding motif. Hence, we 
demonstrate that several of the known disease-associated Z-disk proteins (myotilin, 
myopalladin, FATZ-2, and ZASP) are part of the same structural complex, whose 
composition can be regulated by signaling molecules associated with pathophysiological 
stimuli. Since mutations in these proteins can lead to myopathies, knowledge of their 
protein interactions is highly relevant to understanding muscle and cardiac disorders. 
Myotilin, palladin and myopalladin form a subfamily of Ig-domain-containing actin-
associated proteins, but their actin-binding motifs were not known. Analysis of the 






for other actin-modifying proteins (dos Remedios et al., 2003). Here we identify the Ig-
domains of myotilin as actin-binding motifs also important for actin bundling. Later, also 
palladin, the closest homologue to myotilin, was shown to bind and bundle actin through 
two of its Ig-domains (Dixon et al., 2008). However, the precise mechanism is still 
unknown and needs further investigation. Also the structural data on the actin-binding 
motifs in myotilin and palladin are needed to identify the specific structural features that 
define an actin-binding type of Ig domain. 
The likely mode of pathogenesis in myotilinopathies is via a dominant negative effect 
i.e., the production of “poison” proteins that interfere with the normal function of the 
native myotilin. While myotilin knockout mice lack an obvious phenotype and seem to 
have normal muscle function (Moza et al., 2007), a transgenic mouse strain expressing a 
patient mutation form of myotilin unites the disease phenotype (Garvey et al., 2006). The 
transgenic mice develop myofibrillar pathology progressing with age, including Z-disk 
streaming, myofibrillar vacuolization and myofibrillar aggregation. Protein aggregates 
include transgenic myotilin, endogenous α-actinin, γ-filamin, desmin, titin, and myosin. 
Impaired protein degradation may explain in part the abnormal protein accumulation in 
diseased cells. Therefore, we studied the mechanisms that control myotilin turnover. We 
obtained evidence that myotilin is a calpain substrate and identified two calpain cleavage 
sites in myotilin. In skeletal muscle, calpain cleavage of myotilin could be required for 
reorganization of muscular fibres or for the degradation of myotilin. Based on our 
findings, calpains could mediate the dissociation of myotilin from the assembled 
myofibrillar structure before the ubiquitin-proteasome system is able to degrade the 
protein.  We showed that myotilin was further degraded into small peptides by the 
proteasomal machinery and when this machinery was inhibited, myotilin aggregated 
together with actin in the cells. It would be interesting to test whether these kinds of 
accumulations contain additional proteins aggregated in myotilinopathy and other MFM 
patients. We demonstrated that proteins with myotilinopathy mutations degrade more 
slowly than wt myotilin. The results shown here, for the first time indicate a functional 
difference between wild type and mutated protein, since the patient mutations were more 
resistant to degradation than the wild type protein. We showed that if the degradation of 
myotilin is disturbed, it accumulates in cells in a manner resembling that seen in 
myotilinopathy patients. This is supported by the fact that the amount of myotilin in the 
patient's muscle samples is increased (Barrachina et al., 2007, Shalaby et al., 2009). Based 
on the results, we propose a model on the pathogenic mechanism, by which myotilin 
mutations induce muscular dystrophy.  In this model, mutated myotilin is more resistant to 
degradation, which leads to accumulation of myotilin and induction of actin-containing 
protein aggregates. The aggregates may become toxic when sequestering essential cellular 
proteins and may eventually destroy the myofibers.  This disease mechanism needs, 
however, further investigation in muscle cells. When Conover et al. (2009) transfected 
cardiomyocytes with mutated desmin, a protein found in MFM protein aggregates together 
with myotilin, endogenous desmin often colocalized with aggregates of the mutated form. 
In addition, we did not test all of the known myotilinopathy mutations and there might be 
several molecular mechanisms to cause the disease that starts pathologically with 






myotilin ubiquitinylated by murf-1 or other ubiquitin ligases? What hinders wt myotilin 
from aggregating in the cells? Desmin, for example, is prevented from aggregating under 
various forms of stress by the small heat shock protein alpha-B-crystallin (Perng et al., 
1999). What is clear from these studies is that the cellular defects that lead to 
myotilinopathy are complex and that the mechanism of myopathy may involve alterations 
at many levels, including post-translational modifications and protein turnover. 
It is only under continuous muscle contraction when it becomes apparent that the 
delicate balance between the expression and localization of different sarcomeric proteins 
is crucial for long-term maintenance; an observation that is supported by the data on 
mutated myotilin in humans and resulting different forms of muscle diseases. When there 
is more information about the interplay of sarcomere assembly and disassembly by 
proteolytic systems, the mechanisms of those muscle diseases where the balance of 
myofibril turnover is perturbed will become clearer. It will be important to gain greater 
understanding of both wt and mutated myotilin function through using tissue culture and 
animal models. The ultimate aim is to understand more about muscle structure and 
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